| Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial 2022 · Vitamin D placebo/omega 3 active · Men aged 50 years or older and women aged 55 years or older; general older-adult population | 1 g | 5 years | — |
| Randomized, double-blind, placebo-controlled trial of fish oil and mustard oil in patients with suspected acute myocardial infarction: the Indian experiment of infarct survival--4 1997 · fish oil (group A) · Patients with suspected acute myocardial infarction; age and sex not stated | 1.08 g | 1 year | 122 |
| Oral fish oil positively influences nutritional-inflammatory risk in patients with haematological malignancies during chemotherapy with an impact on long-term survival: a randomised clinical trial 2017 · supplemented group (SG) · Patients with leukaemia or lymphoma beginning chemotherapy; age and sex not reported | 2 g | 9 weeks | 9 |
| Fish-oil supplementation in pregnancy does not reduce the risk of gestational diabetes or preeclampsia 2012 · DHA-enriched fish oil · Pregnant women under 21 weeks of gestation | 800 mg | — | — |
| Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer 2016 · supplemented group (SG) · Adults with colorectal cancer receiving chemotherapy; age and sex not reported | 2 g | 9 weeks | — |
| Fish oil supplementation for primary prevention of atrial fibrillation after coronary artery bypass graft surgery: A randomized clinical trial 2017 · fish oil · Patients undergoing coronary artery bypass graft surgery; age and sex not reported | 2 g | 5 days | — |
| Anti-Wrinkle and Skin Moisture Efficacy of 7-MEGA(TM): A Randomized, Double-Blind, Placebo Comparative Clinical Trial 2024 · 7-MEGA group · Healthy women aged 40–59 years | 1 g | 12 weeks | 50 |
| Synbiotic Supplementation with Probiotics and Omega-3 Fatty Acids Enhances Upper-Body Muscle Strength in Elite Swimmers: Evidence for Gut-Muscle Axis Modulation During Race-Pace Training 2025 · OMEGA + USRPT · Male elite sprint freestyle swimmers with at least 5 years of competitive experience | 1 g | 8 weeks | 10 |
| The effect of acute fish-oil supplementation on endothelial function and arterial stiffness following a high-fat meal 2010 · fish-oil supplement · Healthy men and women; age not reported | 1 g | 1 day | — |
| Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team 2000 · Fish oil, prophylactic trial: twin pregnancy · Pregnant women with twin pregnancies | 2.7 g | — | 579 |
| Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team 2000 · Fish oil, prophylactic trial: previous pregnancy-induced hypertension · Pregnant women with a high-risk pregnancy and a history of pregnancy-induced hypertension | 2.7 g | — | 386 |
| Fish Oil and Vitamin D Supplementations in Pregnancy Protect Against Childhood Croup 2023 · n-3 LCPUFA (fish oil) group · Pregnant women in the Danish population-based Copenhagen Prospective Studies on Asthma in Childhood 2010 mother-child cohort | 2.4 g | 32 weeks | 346 |
| Prenatal Fish Oil Supplementation, Maternal COX1 Genotype, and Childhood Atopic Dermatitis: A Secondary Analysis of a Randomized Clinical Trial 2024 · n-3 LCPUFA (fish oil) group · Pregnant women randomized at 24 weeks’ gestation | 2.4 g | — | 321 |
| Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team 2000 · Fish oil, prophylactic trial: previous intrauterine growth retardation · Pregnant women with a high-risk pregnancy and a history of intrauterine growth retardation | 2.7 g | — | 280 |
| Fish oil and aspirin effects on arteriovenous fistula function: Secondary outcomes of the randomised omega-3 fatty acids (Fish oils) and Aspirin in Vascular access OUtcomes in REnal Disease (FAVOURED) trial 2019 · fish oil · Adults with stage 4 or 5 chronic kidney disease receiving or expected to receive haemodialysis within 12 months and scheduled for arteriovenous fistula surgery | 4 g | 12 weeks | 270 |
| Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team 2000 · Fish oil, prophylactic trial: previous pre-term delivery · Pregnant women with a high-risk pregnancy and a previous pre-term delivery | 2.7 g | — | 232 |
| Effect of supplemented intake of omega-3 fatty acids on arrhythmias in patients with ICD: fish oil therapy may reduce ventricular arrhythmia 2017 · Fish oil · Adults with ischemic cardiomyopathy who had an implantable cardioverter defibrillator | 3.6 g | 26 weeks | 105 |
| Untitled Fish oil group · Adults aged 18 or older with end-stage renal disease receiving chronic hemodialysis and requiring a new synthetic AV-graft | 4 g | 1 year | 101 |
| Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team 2000 · Fish oil, therapeutic trial: threatening pre-eclampsia · Pregnant women with threatening pre-eclampsia | 6.1 g | — | 79 |
| Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186 2008 · Combination therapy (fish oil plus fenofibrate), step 2 · Adults aged 18 or older with HIV infection, taking antiretroviral therapy, and hypertriglyceridemia who did not respond to step-1 monotherapy | 6 g | 8 weeks | 75 |
| Randomised clinical trials of fish oil supplementation in high risk pregnancies. Fish Oil Trials In Pregnancy (FOTIP) Team 2000 · Fish oil, therapeutic trial: suspected intrauterine growth retardation · Pregnant women with suspected intrauterine growth retardation | 6.1 g | — | 63 |
| A controlled trial of fish oil in IgA nephropathy. Mayo Nephrology Collaborative Group 1994 · fish-oil group · Patients with IgA nephropathy and persistent proteinuria | 12 g | 2 years | 55 |
| The effects of dietary supplementation with fish oil on renal function and the course of early postoperative rejection episodes in cyclosporine-treated renal transplant recipients 1992 · Fish oil (EPA+) · First cadaveric renal transplant recipients treated with cyclosporine | 6 g | 30 days | 40 |
| Can n-3 PUFA reduce cardiac arrhythmias? Results of a clinical trial 2004 · fish oil group · Patients with cardiac arrhythmias without coronary heart disease or heart failure; age and sex not reported | 3 g | 26 weeks | 33 |
| Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology 2011 · fish oil group · Patients without clinical atrial fibrillation or structural heart disease, with fish intake no more than once per week; age and sex not reported | 6 g | 30 days | 31 |
| Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial mechanical function after reversion of atrial arrhythmias to sinus rhythm: reversal of tachycardia-mediated atrial cardiomyopathy with fish oils 2011 · omega-3 group · Patients with persistent atrial fibrillation or atrial flutter undergoing reversion to sinus rhythm | 6 g | 10 weeks | 23 |
| Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty 1992 · fish oil group · Patients undergoing a first percutaneous transluminal coronary angioplasty (PTCA); age and sex not reported | 15 g | 29 weeks | — |
| Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil 2007 · Fish oil, groups 1 and 2 · Pregnant women with a previous pregnancy complication or a twin pregnancy; groups 1 and 2 | 2.7 g | — | — |
| Duration of pregnancy in relation to fish oil supplementation and habitual fish intake: a randomised clinical trial with fish oil 2007 · Fish oil, group 3 · Pregnant women with suspicion of intrauterine growth retardation or threatening preeclampsia in the current pregnancy | 6.3 g | — | — |
| Fish oil supplementation during pregnancy and allergic respiratory disease in the adult offspring 2017 · fish oil group · Women in the third trimester of pregnancy | 2.7 g | — | — |
| Fish Oil-Derived Fatty Acids in Pregnancy and Wheeze and Asthma in Offspring 2016 · n-3 LCPUFA (fish oil) group · Pregnant women at 24 weeks of gestation | 2.4 g | — | — |
| A Small Cohort Omega-3 PUFA Supplement Study: Implications of Stratifying According to Lipid Membrane Incorporation in Cardiac Surgical Patients 2017 · Fish oil group · Patients undergoing elective coronary artery graft or valve surgery; age and sex not specified | 3 g | 20 days | — |
| Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder 2022 · low-dose Omega 3-6 treatment group · Children aged 2 to under 6 years recently diagnosed with severe-range autism spectrum disorder | 25 mg/kg | 90 days | — |
| Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder 2022 · medium-dose Omega 3-6 treatment group · Children aged 2 to under 6 years recently diagnosed with severe-range autism spectrum disorder | 50 mg/kg | 90 days | — |
| Randomized Controlled Trial of Omega-3 and -6 Fatty Acid Supplementation to Reduce Inflammatory Markers in Children with Autism Spectrum Disorder 2022 · high-dose Omega 3-6 treatment group · Children aged 2 to under 6 years recently diagnosed with severe-range autism spectrum disorder | 100 mg/kg | 90 days | — |
| [Fish oil supplementation and duration of pregnancy. A randomized controlled trial] 1994 · fish oil · Healthy pregnant Danish women assigned in the 30th week of pregnancy | 2.7 g | — | — |
| Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency 1996 · fish oil group · Patients undergoing coronary artery bypass grafting | 4 g | 1 year | — |
| Omega-3 fatty acid supplements improve the cardiovascular risk profile of subjects with metabolic syndrome, including markers of inflammation and auto-immunity 2009 · fish-oil intervention group · Adults with metabolic syndrome; mean age 52.9 years; sex not specified | 1 g | 26 weeks | 60 |
| The effects of fish oil capsules and vitamin B1 tablets on duration and severity of dysmenorrhea in students of high school in Urmia-Iran 2014 · fish oil group · Females aged 13–18 years with dysmenorrhea and low dietary fish intake | 500 mg | 60 days | 60 |
| Adjunctive treatment of chronic periodontitis with daily dietary supplementation with omega-3 Fatty acids and low-dose aspirin 2010 · ω-3 group · Adults with advanced chronic periodontitis | 900 mg | 26 weeks | 40 |
| Feasibility of Fish Oil Supplementation on Headache Symptoms and Blood Lipids in Migraine Patients 2024 · Test group · Adults aged 20–65 years with episodic migraine; both sexes | 2 g | 12 weeks | 24 |
| The effect of fish oil versus krill oil intervention on clinical symptoms and cardiometabolic risk factors in patients with major depressive disorder: A randomized placebo-controlled double-blind trial 2025 · fish-oil group · Adults diagnosed with major depressive disorder | 600 mg | 8 weeks | 17 |
| Effects of krill oil containing n-3 polyunsaturated fatty acids in phospholipid form on human brain function: a randomized controlled trial in healthy elderly volunteers 2013 · sardine oil group · Healthy men in their 60s and 70s without cognitive impairment | 2 g | 12 weeks | 14 |
| Impact of Varying Dosages of Fish Oil on Recovery and Soreness Following Eccentric Exercise 2020 · 2G fish oil group · Recreationally active men and women, mean ages about 23 years, apparently healthy and without a stated disease | 2 g | 53 days | 8 |
| Untitled 2012 · ST90 group · Women aged 64 ± 1.4 years | 2 g | 90 days | — |
| Untitled 2012 · ST150 group · Women aged 64 ± 1.4 years | 2 g | 150 days | — |
| Fish oil (n-3 fatty acids) in drug resistant epilepsy: a randomised placebo-controlled crossover study 2015 · low-dose fish oil · People with drug-resistant epilepsy; age and sex not reported | 1.08 g | 10 weeks | — |
| Effects of n-3 long-chain PUFA supplementation to lactating mothers and their breastfed children on child growth and morbidity: a 2 × 2 factorial randomized controlled trial in rural Ethiopia 2018 · MCI (mother and child receiving fish oil intervention) · Lactating mothers and breastfed children aged 6–12 months at enrollment in rural Ethiopia | 500 mg | 1 year | — |
| Effects of n-3 long-chain PUFA supplementation to lactating mothers and their breastfed children on child growth and morbidity: a 2 × 2 factorial randomized controlled trial in rural Ethiopia 2018 · MI (mother receiving fish oil intervention; child receiving placebo control) · Lactating mothers and their breastfed children aged 6–12 months at enrollment in rural Ethiopia | 500 mg | 1 year | — |
| Effects of n-3 long-chain PUFA supplementation to lactating mothers and their breastfed children on child growth and morbidity: a 2 × 2 factorial randomized controlled trial in rural Ethiopia 2018 · CI (child receiving fish oil intervention; mother receiving placebo control) · Breastfed children aged 6–12 months at enrollment in rural Ethiopia and their lactating mothers | 500 mg | 1 year | — |
| Identification of individuals who benefit from omega-3 fatty acid supplementation to prevent coronary heart disease: a machine-learning analysis of the VITAL 2025 · omega-3 FA supplementation arm · US men aged 50 years or older and women aged 55 years or older in a primary-prevention trial | 1 g | 5 years | 12,933 |
| The impact of pre- and postnatal exposures on allergy related diseases in childhood: a controlled multicentre intervention study in primary health care 2013 · intervention cohort · Pregnant women and their children in the general population of Trondheim; no age range or sex restriction stated | 5 mL | — | 1,374 |
| Effect of n-3 long chain polyunsaturated fatty acid supplementation in pregnancy on infants' allergies in first year of life: randomised controlled trial 2012 · n-3 LCPUFA group · Pregnant women from Adelaide whose unborn baby had a mother, father, or sibling with a history of medically diagnosed allergic disease | 1.5 g | — | 368 |
| Fish oil intake compared with olive oil intake in late pregnancy and asthma in the offspring: 16 y of registry-based follow-up from a randomized controlled trial 2008 · fish oil · Women with normal pregnancies, recruited around gestation week 30 | 4 g | — | 266 |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 1 g | 1936 days | — |
| Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer 2019 · n-3 fatty acids plus vitamin D group · Men aged 50 years or older and women aged 55 years or older, without selection for cardiovascular risk factors, in a primary-prevention trial | 1 g | 1936 days | — |
| Vitamin D and marine omega 3 fatty acid supplementation and incident autoimmune disease: VITAL randomized controlled trial 2022 · Vitamin D active/omega 3 active · Men aged 50 years or older and women aged 55 years or older; general older-adult population, not selected for vitamin D deficiency | 1 g | 5 years | — |
| Marine n-3 polyunsaturated fatty acids slow sleep impairment progression by regulating central circadian rhythms in type 2 diabetes 2025 · low-dose fish oil use group · Adults aged 40–75 with diagnosed type 2 diabetes | 1.5 g | 426 days | 140 |
| Marine n-3 polyunsaturated fatty acids slow sleep impairment progression by regulating central circadian rhythms in type 2 diabetes 2025 · high-dose fish oil use group · Adults aged 40–75 with diagnosed type 2 diabetes | 3 g | 426 days | 137 |
| The effects of fish oil capsules and vitamin B1 tablets on duration and severity of dysmenorrhea in students of high school in Urmia-Iran 2014 · combination therapy group · Females aged 13–18 years with dysmenorrhea and low dietary fish intake | 500 mg | 60 days | 60 |
| A Randomized, Double-blind, Placebo-controlled Clinical Study to Investigate the efficacy of Herring Roe Oil for treatment of Psoriasis 2020 · HRO · Adults aged 18 years or older with stable plaque psoriasis and PASI scores below 10 | 5.9 g | 26 weeks | 32 |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 2 g | 16 weeks | 31 |
| Sex differences in the effect of fish-oil supplementation on the adaptive response to resistance exercise training in older people: a randomized controlled trial 2017 · long-chain n–3 PUFA group · Older medically stable men and women; men aged 71.5 ± 5.1 years in the placebo group and women aged 69.8 ± 4.0 years, with no stated disease | 3 g | 18 weeks | 27 |
| Perna canaliculus lipid complex PCSO-524™ demonstrated pain relief for osteoarthritis patients benchmarked against fish oil, a randomized trial, without placebo control 2013 · Group B (fish oil; Stage I) · Adults older than 50 years, both sexes, with clinically diagnosed knee and/or hip osteoarthritis | 300 mg | 12 weeks | 25 |
| Long chain omega 3 polyunsaturated fatty acids supplementation in the treatment of elderly depression: effects on depressive symptoms, on phospholipids fatty acids profile and on health-related quality of life 2011 · n-3 group · Institutionalized females aged 65–95 with major depression or dysthymia | 2.5 g | 8 weeks | 22 |
| Prior supplementation with long chain omega-3 polyunsaturated fatty acids promotes weight loss in obese adults: a double-blinded randomised controlled trial 2013 · fish oil group · Obese adults; age range and sex distribution not stated | 6 g | 8 weeks | 20 |
| Fish oil-supplementation increases appetite in healthy adults. A randomized controlled cross-over trial 2013 · fish oil · Normal-weight healthy adults; 20 participants, 50% female | 5 mL | 3 weeks | 20 |
| Effect of Clupeonella grimmi (anchovy/kilka) fish oil on dysmenorrhoea 2010 · Group A (fish oil) · Girls aged 18–22 with dysmenorrhoea | 15 mL | 90 days | 18 |
| Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human pulmonary vein and left atrial electrophysiology in paroxysmal atrial fibrillation 2011 · fish oil group · Patients with paroxysmal atrial fibrillation undergoing pulmonary vein isolation | 6 g | 40 days | 18 |
| Randomised Controlled Trial of Fish Oil Supplementation on Responsiveness to Resistance Exercise Training in Sarcopenic Older Women 2022 · Group Exercise and Fish Oil (EFO) · Women aged 65 years or older with sarcopenia who were sedentary and had BMI below 30 kg/m² | 4 g | 14 weeks | 17 |
| Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia 2008 · Group 2: rosuvastatin plus omega-3 fatty acids after rosuvastatin alone · South Asian adults aged 25–80 with dyslipidemia and abnormal endothelial function; with or without established coronary artery disease | 4.53 g | 4 weeks | 16 |
| Fish oil blunts lung function decrements induced by acute exposure to ozone in young healthy adults: A randomized trial 2022 · FO group · Healthy adults aged 18–35 years with low background omega-3 status and normal lung function | 3 g | 4 weeks | 15 |
| Omega-3 fatty acids plus rosuvastatin improves endothelial function in South Asians with dyslipidemia 2008 · Group 1: rosuvastatin plus omega-3 fatty acids · South Asian adults aged 25–80 with dyslipidemia and abnormal endothelial function; with or without established coronary artery disease | 4.53 g | 4 weeks | 14 |
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer 2007 · fish oil + placebo · Patients with advanced lung cancer and systemic immune-metabolic syndrome; age and sex not reported | 6 g | 6 weeks | 12 |
| DHA-rich fish oil lowers heart rate during submaximal exercise in elite Australian Rules footballers 2009 · DHA-rich fish oil (FO) · Elite Australian Rules football players; age and sex not specified | 6 g | 5 weeks | 12 |
| Effects of Omega-3 Supplementation on the Delayed Onset Muscle Soreness after Cycling High Intensity Interval Training in Overweight or Obese Males 2024 · omega-3 (O3) · Sedentary, untrained males with overweight or obesity | 4 g | 4 weeks | 12 |
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer 2007 · fish oil + celecoxib · Patients with advanced lung cancer and systemic immune-metabolic syndrome; age and sex not reported | 6 g | 6 weeks | 10 |
| [Should I also eat fish oils? A critical assessment of the use of fish oils in the prevention of ischemic heart disease] 1992 · fish oil supplement · Adults aged 30–55 years; no specific condition reported | 6 g | 4 weeks | 9 |
| Fish oil reduces heart rate and oxygen consumption during exercise 2008 · FO · Well-trained men who were cyclists; ages 23.2 ± 1.2 years in this arm | 8 g | 8 weeks | 9 |
| Impact of Varying Dosages of Fish Oil on Recovery and Soreness Following Eccentric Exercise 2020 · 4G fish oil group · Recreationally active men and women, mean ages about 23 years, apparently healthy and without a stated disease | 4 g | 53 days | 8 |
| Impact of Varying Dosages of Fish Oil on Recovery and Soreness Following Eccentric Exercise 2020 · 6G fish oil group · Recreationally active men and women, mean ages about 23 years, apparently healthy and without a stated disease | 6 g | 53 days | 8 |
| Efficacy of fish oil concentrate in the treatment of rheumatoid arthritis 2000 · Fish oil group · Adults with rheumatoid arthritis whose background dietary n-6 fatty acid intake was less than 10 g/day | 40 mg/kg | 15 weeks | — |
| Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis 2003 · fish oil 3000 mg daily · Adults with periodontitis | 3 g | 12 weeks | — |
| The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus 2004 · 3 g MaxEPA and placebo copper · patients with systemic lupus erythematosus | 3 g | 24 weeks | — |
| Effect of six months of fish oil supplementation in stable rheumatoid arthritis. A double-blind, controlled study 1992 · fish oil group · Patients with stable rheumatoid arthritis; age and sex not specified | 10 g | 26 weeks | — |
| Maternal fish oil supplementation in lactation and growth during the first 2.5 years of life 2005 · fish oil group · Lactating Danish mothers with fish intake below the population median | 4.5 g | 122 days | — |
| Fish oil fatty acids improve postprandial vascular reactivity in healthy men 2008 · fish oil meal · healthy men; age not reported | 9 g | 1 day | — |
| A placebo-controlled, double-blind study of eicosapentaenoic acid-rich fish oil in patients with stable angina pectoris 1990 · fish oil group · patients with stable angina pectoris; age and sex not stated | 2.8 g | 90 days | — |
| Omega-3 fatty acids reduce adipose tissue macrophages in human subjects with insulin resistance 2013 · Omega-3-Acid Ethyl Esters (fish oil) group · Nondiabetic adults with impaired glucose tolerance, impaired fasting glucose, or at least three features of metabolic syndrome; participants had obesity and insulin resistance | 4 g | 12 weeks | — |
| Fish oil-supplementation from 9 to 12 months of age affects infant attention in a free-play test and is related to change in blood pressure 2013 · +fish oil · 9-month-old infants | 3.4 mL | 90 days | — |
| The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical trial 2015 · 6 g fish oil without a multivitamin · Healthy adults aged 50–70 years | 6 g | 16 weeks | — |
| Omega-3 Levels and Nicotine Dependence: A Cross-Sectional Study and Clinical Trial 2016 · fish oil (omega-3) group · adult smokers; age and sex not specified | 3 g | 90 days | — |
| Fish Oil Supplementation Enhances Pulmonary Strength and Endurance in Women Undergoing Chemotherapy 2016 · FO supplemented (S) group · Women with breast cancer beginning chemotherapy; age range not reported | 4 g | 60 days | — |
| Effects of fish oil-derived fatty acids on suboptimal cardiovascular health: A multicenter, randomized, double-blind, placebo-controlled trial 2017 · n-3 LCPUFA group · Participants with suboptimal cardiovascular health recruited from two clinics in China; ages and sex not reported | 4 g | 90 days | — |
| Omega-3 fatty acid supplementation may prevent loss of gray matter thickness in the left parieto-occipital cortex in first episode schizophrenia: A secondary outcome analysis of the OFFER randomized controlled study 2018 · concentrated fish oil · people with first-episode schizophrenia | 2.2 g | 26 weeks | — |
| Comparative effectiveness of adding Omega-3 or Vitamin D to standard therapy in preventing and treating episodes of painful crisis in pediatric sickle cell patients 2022 · Omega-3 group · Children with sickle cell disease | 3 g | 304 days | — |
| Effects of fish oil-derived n-3 polyunsaturated fatty acid on body composition, muscle strength and physical performance in older people: a secondary analysis of a randomised, double-blind, placebo-controlled trial 2022 · fish oil group · Older Chinese people; age and sex distribution and health conditions not specified in the abstract | 4 g | 26 weeks | — |
| Fish oil supplementation during pregnancy and postpartum in mothers with overweight and obesity to improve body composition and metabolic health during infancy: A double-blind randomized controlled trial 2023 · fish oil supplementation · Pregnant women with singleton pregnancies, enrolled at 12–20 weeks’ gestation, with overweight or obesity (BMI ≥25 kg/m²) | 6 g | — | — |
| Fish oil supplementation during pregnancy, anthropometrics, and metabolic health at age ten: A randomized clinical trial 2024 · n-3 LCPUFA group · Pregnant females and their offspring; maternal supplementation during pregnancy | 2.4 g | — | — |
| Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans 1993 · 20 g/day maxEPA · healthy adult men | 20 g | 4 weeks | — |
| Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans 1993 · 10 g/day maxEPA · healthy adult men | 10 g | 4 weeks | — |
| Marine oils dose-dependently inhibit vasoconstriction of forearm resistance vessels in humans 1993 · 5 g/day maxEPA · healthy adult men | 5 g | 4 weeks | — |
| Effects of n-3 fatty acid supplements on glycemic traits in Chinese type 2 diabetic patients: A double-blind randomized controlled trial 2016 · fish oil (FO) group · Chinese adults with type 2 diabetes | 2 g | 180 days | 63 |
| Lowering Effects of n-3 Fatty Acid Supplements on Blood Pressure by Reducing Plasma Angiotensin II in Inner Mongolia Hypertensive Patients: A Double-Blind Randomized Controlled Trial 2019 · fish oil group · Chinese adults with hypertension from Inner Mongolia; age range and sex not specified | 2 g | — | 41 |
| Moderate consumption of fatty fish reduces diastolic blood pressure in overweight and obese European young adults during energy restriction 2010 · fish oil capsules · Adults aged 20–40 years with BMI 27.5–32.5 kg/m² who were overweight or obese, from Iceland, Spain, and Ireland | 1.3 g | 8 weeks | — |
| Effects of fish oil supplementation on markers of the metabolic syndrome 2010 · fish oil (FO group) · boys aged 13–15 years with mean body fat percentage of 30% ± 9%, described as slightly overweight | 1.5 g | 16 weeks | — |
| An Exploratory Analysis of Changes in Mental Wellbeing Following Curcumin and Fish Oil Supplementation in Middle-Aged and Older Adults 2020 · FO + CUR group · Adults aged 50–80 years who were overweight or obese, sedentary, and without current major depression | 2 g | 16 weeks | 30 |
| Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial 2023 · Multidomain plus omega 3 · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed | 400 mg | 3 years | 129 |
| Effects of Varied Omega-3 Fatty Acid Supplementation on Postpartum Mental Health and the Association between Prenatal Erythrocyte Omega-3 Fatty Acid Levels and Postpartum Mental Health 2023 · fish oil group · Healthy primiparous pregnant women aged 19–45 years | 5.2 g | 12 weeks | 124 |
| Cognitive impact of multidomain intervention and omega 3 according to blood Aβ42/40 ratio: a subgroup analysis from the randomized MAPT trial 2023 · Omega 3 alone · Adults aged 70 years and over, non-demented, with memory complaint, limitation in one instrumental activity of daily living, or slow gait speed | 400 mg | 3 years | 112 |
| Long-chain PUFA supplementation in rural African infants: a randomized controlled trial of effects on gut integrity, growth, and cognitive development 2013 · fish-oil group · Gambian infants, approximately 3–9 months old, living in rural West Kiang; no specific diagnosed condition required | 2 mL | 26 weeks | 87 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Fish oil + placebo · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 4.8 g | — | 82 |
| Fish Oil And/Or Probiotics Intervention in Overweight/Obese Pregnant Women and Overweight Risk in 24-Month-Old Children 2023 · Probiotics + fish oil · Pregnant women with overweight or obesity, enrolled before 18 gestational weeks; no chronic diseases stated | 4.8 g | — | 82 |
| Effects of Concentrated Long-Chain Omega-3 Polyunsaturated Fatty Acid Supplementation on Quality of Life after Radical Prostatectomy: A Phase II Randomized Placebo-Controlled Trial (RCT-EPA) 2023 · MAG-EPA intervention group · Adult men with aggressive localized prostate cancer (Gleason score ≥ 7, ISUP Grade group ≥ 2) treated by radical prostatectomy | 3.75 g | 1 year | 65 |
| Untitled 2012 · omega-3 PUFA · Healthy adults aged 51–72 years, women and men, with BMI 20–30 kg/m² and no known metabolic disease or cognitive decline | 5 g | 5 weeks | 38 |
| Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years 2020 · FO · Healthy pregnant women; offspring were assessed at 7.5 and 9 years | 150 mg | — | 38 |
| Long-Chain Polyunsaturated Fatty Acids, Homocysteine at Birth and Fatty Acid Desaturase Gene Cluster Polymorphisms are Associated with Children's Processing Speed up to Age 9 Years 2020 · FO + 5-MTHF · Healthy pregnant women; offspring were assessed at 7.5 and 9 years | 150 mg | — | 36 |
| A 12-week randomized double-blind clinical trial of eicosapentaenoic acid intervention in episodic migraine 2024 · EPA group · Adults with episodic migraine; age and sex range not reported | 2 g | 12 weeks | 35 |
| Effects of ω-3 PUFAs supplementation on myocardial function and oxidative stress markers in typical Rett syndrome 2014 · ω-3 PUFAs arm · Girls aged 12.7 ± 9.1 years on average with typical Rett syndrome and a demonstrated MeCP2 mutation | 10 mL | 1 year | 33 |
| Effect of Docosahexaenoic Acid and Eicosapentaenoic Acid Supplementation on Sleep Quality in Healthy Subjects: A Randomized, Double-Blinded, Placebo-Controlled Trial 2022 · DHA/EPA supplementation group · Healthy Japanese adults aged 45 years or older with poor sleep quality; male and female | 2.88 g | 12 weeks | 33 |
| Effects of omega-3 fatty acid supplementation on cigarette craving and oxidative stress index in heavy-smoker males: A double-blind, randomized, placebo-controlled clinical trial 2018 · fish-oil-derived omega-3 fatty acid supplements · heavy-smoker males who smoked at least 20 cigarettes per day | 5 g | 90 days | 27 |
| Fish oil supplementation alters emotion-generated corticolimbic functional connectivity in depressed adolescents at high-risk for bipolar I disorder: A 12-week placebo-controlled fMRI trial 2022 · FO group · Youth aged 9–21 years with major depressive disorder or Depressive Disorder NOS and a biological parent with bipolar I disorder | 1.35 g | 12 weeks | 27 |
| Placebo-controlled randomized clinical trial of fish oil's impact on fatigue, quality of life, and disease activity in Systemic Lupus Erythematosus 2015 · fish oil · Adults aged 18–64 with systemic lupus erythematosus | 2.25 g | 26 weeks | 25 |
| Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial 2020 · TG1 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis | 3 g | 60 days | 25 |
| Omega-3 PUFA and aspirin as adjuncts to periodontal debridement in patients with periodontitis and type 2 diabetes mellitus: Randomized clinical trial 2020 · TG2 · Adults aged 35 or older with type 2 diabetes and moderate-to-severe generalized chronic periodontitis | 3 g | 60 days | 25 |
| The effects of EPA and DHA enriched fish oil on nutritional and immunological markers of treatment naïve breast cancer patients: a randomized double-blind controlled trial 2017 · Fish oil group (FG) · Women aged 18–70 with newly diagnosed, treatment-naïve breast cancer before surgery | 2 g | 30 days | 18 |
| [Polyunsaturated omega-3 fatty acids in the treatment of experimental human gingivitis] 1996 · treatment group · Healthy volunteers; age and sex not specified; no stated condition | 6 g | 7 days | 18 |
| Pilot study on n-3 polyunsaturated fatty acids in the treatment of human experimental gingivitis 1997 · drug (fish oil) group · Healthy volunteers with experimentally induced gingivitis; age and sex not stated | 6 g | 8 days | 18 |
| Supplementation of l-Alanyl-l-Glutamine and Fish Oil Improves Body Composition and Quality of Life in Patients With Chronic Heart Failure 2015 · Combination of L-alanyl-L-glutamine and fish oil · Adults older than 45 years with stable chronic heart failure and left ventricular ejection fraction ≤35% | 6.5 g | 90 days | 17 |
| Fish oil supplemented for 9 months does not improve glycaemic control or insulin sensitivity in subjects with impaired glucose regulation: a parallel randomised controlled trial 2016 · Fish oil (FO) · Adults with impaired glucose regulation; age and sex not reported | 6 g | 270 days | 16 |
| Effects of dietary supplementation with fish oil on dry eye syndrome subjects: randomized controlled trial 2013 · fish oil group · People with dry eye syndrome | 1.25 g | 12 weeks | 15 |
| Fish Oil Supplementation Increases Event-Related Posterior Cingulate Activation in Older Adults with Subjective Memory Impairment 2016 · Fish oil group · Older adults with subjective memory impairment, without mild cognitive impairment or dementia; age range and sex distribution not specified | 2.4 g | 24 weeks | 15 |
| Effects of omega-3 supplementation as an adjunct to non-surgical periodontal therapy on periodontal parameters in periodontitis patients: a randomized clinical trial 2022 · Intervention group · Adults aged 30–70 with stage II–IV, grade B periodontitis | 1 g | 90 days | 15 |
| Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: a randomized pilot study 2005 · fish oil group · Patients with advanced gastrointestinal cancer, documented weight loss and/or decreased serum albumin, not amenable to standard anticancer treatment | 30 mL | 8 weeks | 13 |
| Omega-3 Fatty Acid Supplementation for 12 Weeks Increases Resting and Exercise Metabolic Rate in Healthy Community-Dwelling Older Females 2015 · fish oil (FO) · Community-dwelling females aged 60–76 years in generally good health, with low fish intake and no omega-3 supplement use | 5 g | 12 weeks | 12 |
| Eicosapentaenoic and docosahexaenoic acids-rich fish oil supplementation attenuates strength loss and limited joint range of motion after eccentric contractions: a randomized, double-blind, placebo-controlled, parallel-group trial 2016 · EPA group · Healthy Japanese men, mean age 19.4 years; no stated diagnosed condition | 2.4 g | 62 days | 12 |
| Resting metabolic rate and skeletal muscle SERCA and Na(+) /K(+) ATPase activities are not affected by fish oil supplementation in healthy older adults 2020 · Fish oil group · Healthy physically active men and women aged 60–75 years | 5 g | 12 weeks | 12 |
| Randomized controlled trial of fish oil and montelukast and their combination on airway inflammation and hyperpnea-induced bronchoconstriction 2010 · Fish Oil · Adults aged 18–27 with physician-diagnosed mild-to-moderate persistent asthma and documented hyperpnea-induced bronchoconstriction | 5.2 g | 3 weeks | 10 |
| Effect of eicosapentaenoic acids-rich fish oil supplementation on motor nerve function after eccentric contractions 2017 · EPA group · Healthy men, mean age 20.7 years; untrained and without a stated diagnosed condition | 2.4 g | 62 days | 10 |
| Omega-3 fatty acids enhance the beneficial effect of BCAA supplementation on muscle function following eccentric contractions 2022 · BCAA+FO group · Healthy, untrained men aged 19–20 years | 2.4 g | 61 days | 10 |
| The effect of fish oil supplementation on resistance training-induced adaptations 2023 · Fish Oil (FOS) · Adults aged 18–40, men and women, recreationally resistance-trained, without stated chronic disease | 4.5 g | 10 weeks | 10 |
| Fish Oil Supplementation with Resistance Exercise Training Enhances Physical Function and Cardiometabolic Health in Postmenopausal Women 2023 · RET-FO · Healthy postmenopausal women, mean age 65.65 ± 3.39 years | 2.82 g | 8 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Omega-3 + USRPT (OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 1 g | 8 weeks | 10 |
| Synbiotic Supplementation with Probiotics and Omega-3 Fatty Acids Enhances Upper-Body Muscle Strength in Elite Swimmers: Evidence for Gut-Muscle Axis Modulation During Race-Pace Training 2025 · PRO + OMEGA + USRPT · Male elite sprint freestyle swimmers with at least 5 years of competitive experience | 1 g | 8 weeks | 10 |
| Supplementation of eicosapentaenoic acid-rich fish oil attenuates muscle stiffness after eccentric contractions of human elbow flexors 2019 · EPA group · Healthy men, approximately 20–22 years old, without resistance training | 2.4 g | 62 days | 8 |
| Fish oil supplementation reduces severity of exercise-induced bronchoconstriction in elite athletes 2003 · n-3 PUFA diet · Elite athletes, including athletes with exercise-induced bronchoconstriction (EIB) and athletes without EIB; age and sex not reported | 3.2 g | 3 weeks | 5 |
| Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids 2001 · dietary n-3FA therapy · Patients with sickle cell disease; age and sex not stated | 250 mg/kg | 30 days | — |
| Pilot study of dietary fatty acid supplementation in the treatment of adult periodontitis 2003 · fish oil 1500 and borage oil 1500 mg daily · Adults with periodontitis | 1.5 g | 12 weeks | — |
| Treatment of ulcerative colitis with fish oil supplementation: a prospective 12 month randomised controlled trial 1992 · fish oil · Patients with ulcerative colitis, including patients entering in relapse and patients in remission | 20 mL | 1 year | — |
| The clinical effect of dietary supplementation with omega-3 fish oils and/or copper in systemic lupus erythematosus 2004 · 3 g MaxEPA and 3 mg copper · patients with systemic lupus erythematosus | 3 g | 24 weeks | — |
| Effects of fish oil on the neuro-endocrine responses to an endotoxin challenge in healthy volunteers 2007 · fish oil supplementation · Healthy men aged 26.0 ± 3.1 years | 7.2 g | 4 weeks | — |
| Treatment for 2 mo with n 3 polyunsaturated fatty acids reduces adiposity and some atherogenic factors but does not improve insulin sensitivity in women with type 2 diabetes: a randomized controlled study 2007 · fish oil group · Women with type 2 diabetes without hypertriglyceridemia | 3 g | 60 days | — |
| Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults 2008 · Fish oil, no regular physical activity · Sedentary, overweight adults with risk factors for coronary disease | 6 g | 12 weeks | — |
| Docosahexaenoic acid-rich fish oil improves heart rate variability and heart rate responses to exercise in overweight adults 2008 · Fish oil with regular physical activity · Sedentary, overweight adults with risk factors for coronary disease | 6 g | 12 weeks | — |
| omega-3 Fatty acids infusions as adjuvant therapy in rheumatoid arthritis 2010 · active treatment group · Adults with moderate to severe active rheumatoid arthritis | 50 mg/kg | 22 weeks | — |
| The effect of low-dose omega 3 fatty acids on the treatment of mild to moderate depression in the elderly: a double-blind, randomized, placebo-controlled study 2011 · drug group · Adults aged 65 years or older with mild to moderate depression | 1 g | 26 weeks | — |
| Fish oil supplementation improves neutrophil function during cancer chemotherapy 2012 · FO · Cancer patients receiving chemotherapy after surgical tumor removal, mainly gastrointestinal cancers; age and sex not stated | 2 g | 8 weeks | — |
| The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical trial 2015 · 3 g fish oil with a multivitamin · Healthy adults aged 50–70 years | 3 g | 16 weeks | — |
| The effects of long-chain omega-3 fish oils and multivitamins on cognitive and cardiovascular function: a randomized, controlled clinical trial 2015 · 6 g fish oil with a multivitamin · Healthy adults aged 50–70 years | 6 g | 16 weeks | — |
| Effect of Docosahexaenoic Acid (DHA) Supplementation of Preterm Infants on Growth, Body Composition, and Blood Pressure at 7-Years Corrected Age: Follow-Up of a Randomized Controlled Trial 2023 · high-DHA diet (intervention) · Preterm infants born before 33 weeks gestation and their breastfeeding mothers; enrolled within 5 days of commencing enteral feeds | 3 g | — | — |
| Omega-3 polyunsaturated fatty acids supplementation improves memory in first-diagnosed, drug-naïve patients with depression: Secondary analysis of data from a randomized controlled trial 2024 · n-3 PUFAs supplementation · Outpatients with first-diagnosed, drug-naïve depression receiving venlafaxine; age and sex not reported | 2.4 g | 12 weeks | — |
| Effects of fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis--a double-blind placebo controlled study 1993 · Maxepa · Patients with stable mild rheumatoid arthritis requiring NSAID therapy only; age and sex not reported | 1.71 g | 1 year | — |
| Effect of dietary supplementation with very-long-chain n-3 fatty acids in patients with psoriasis 1993 · fish-oil group · Patients with moderate-to-severe psoriasis; age and sex not specified | 6 g | 120 days | — |
| Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine 2018 · Nutraceuticals (NTR) · Adults with dyslipidemia and type 2 diabetes treated with statins and hypoglycemic medication; mean age 63.8 years, 19 men and 34 women | 1.7 g | 6 weeks | 53 |
| Reduction of cardiovascular risk factors by the diet - Evaluation of the MoKaRi concept by a parallel-designed randomized study 2025 · Menu plan plus fish oil (MP-FO) · Men and women aged 20–80 years with plasma LDL cholesterol ≥3 mmol/L and no lipid-lowering therapy | 3 g | 20 weeks | 25 |
| Lack of effect of fish oil supplementation on blood pressure in treated hypertensives 1990 · Fish oil phase · Treated hypertensive adults with controlled blood pressure | 15 g | 8 weeks | 20 |
| Fish oil amplifies the effect of propranolol in mild essential hypertension 1990 · Second subgroup: fish oil · Men with mild essential hypertension | 9 g | 36 weeks | 15 |
| Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine 2018 · Responders receiving nutraceuticals with half-dose statin therapy (HDS) · Adults with dyslipidemia and type 2 diabetes treated with statins and hypoglycemic medication, classified as nutraceutical responders; 3 men and 7 women, mean age 62.1 years | 1.7 g | 6 weeks | 10 |
| Different effects of eicosapentaenoic acid and olive oil on blood pressure, intracellular free platelet calcium, and plasma lipids in patients with essential hypertension 1993 · fish oil · Adults with WHO class I or II essential hypertension | 9 g | 6 weeks | 10 |
| Effects of n-3 fatty acids in essential hypertension 1990 · marine oil · Patients with mild essential hypertension | 50 g | 6 weeks | 8 |
| Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects 2003 · SFA diet plus fish oil · Healthy people; age range and sex not reported | 3.6 g | — | — |
| Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects 2003 · MUFA diet plus fish oil · Healthy people; age range and sex not reported | 3.6 g | — | — |
| Effects of a fish oil supplement on blood pressure and serum lipids in patients treated for coronary artery disease 1992 · MaxEPA (fish oil) group · Patients treated for coronary artery disease; age and sex not stated | 15 g | 26 weeks | — |
| Fish oil affects blood pressure and the plasma lipid profile in healthy Danish infants 2006 · fish oil · Healthy term infants aged 9 months | 5 mL | 90 days | — |
| Effects of omega-3 fatty acid supplementation on lipid levels in endstage renal disease patients 2009 · Fish-oil group · Adults with endstage renal disease | 6 g | 26 weeks | — |
| Effect of eicosapentaenoic and docosahexaenoic acids on blood pressure in hypertension. A population-based intervention trial from the Tromsø study 1990 · fish oil group · men and women with previously untreated stable, mild essential hypertension | 6 g | 10 weeks | — |
| Fish oil as an adjuvant in the treatment of hypertension 1996 · fish oil · men with suboptimally controlled hypertension who were taking antihypertensive agents | 4.5 g | 8 weeks | — |
| Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation 2015 · Study 1: 300 mg/day EPA + DHA · Healthy adults aged 20–45 years with low or no habitual oily-fish consumption | 1 g | 20 weeks | — |
| The effects of omega-3 fatty acids on neuropsychological functioning and brain morphology in mid-life adults: a randomized clinical trial 2020 · fish oil group · Adults aged 30–54 years with low dietary EPA and DHA intake and no stated diagnosed condition | 2 g | 18 weeks | 134 |
| The impact of supplemental n-3 long chain polyunsaturated fatty acids and dietary antioxidants on physical performance in postmenopausal women 2013 · n-3 LCPUFA group · Postmenopausal women over age 65 without the listed bone, cancer or liver diseases; most were prefrail or frail. | 1.2 g | 180 days | 85 |
| Wrinkle reduction in post-menopausal women consuming a novel oral supplement: a double-blind placebo-controlled randomized study 2014 · Test group 1 · Healthy, non-smoking post-menopausal women, skin types I–III, not receiving HRT and with BMI 18–33 kg/m² | 660 mg | 14 weeks | 55 |
| Wrinkle reduction in post-menopausal women consuming a novel oral supplement: a double-blind placebo-controlled randomized study 2014 · Test group 2 · Healthy, non-smoking post-menopausal women, skin types I–III, not receiving HRT and with BMI 18–33 kg/m² | 660 mg | 14 weeks | 55 |
| Predictors of treatment response in young people at ultra-high risk for psychosis who received long-chain omega-3 fatty acids 2015 · ω-3 PUFA group · People aged 13–25 with ultra-high risk for psychosis | 2 g | 12 weeks | 40 |
| Omega-3 fatty acid, carotenoid and vitamin E supplementation improves working memory in older adults: A randomised clinical trial 2022 · active group · Cognitively healthy adults aged 65 years and older | 1 g | 2 years | 30 |
| Interindividual variability in response to protein and fish oil supplementation in older adults: a randomized controlled trial 2022 · LEU-PRO + n-3 · Adults aged 65 years or older at risk of sarcopenia; men and women | 3.8 g | 24 weeks | 30 |
| Lipid Profile, Lipoprotein Subfractions, and Fluidity of Membranes in Children and Adolescents with Depressive Disorder: Effect of Omega-3 Fatty Acids in a Double-Blind Randomized Controlled Study 2020 · Om3 group · Children and adolescents aged 11–17 years with depressive disorder or mixed anxiety and depressive disorder | 20 mL | 12 weeks | 29 |
| Effect of Omega-3 Polyunsaturated Fatty Acid Supplementation on Clinical Outcome of Atopic Dermatitis in Children 2024 · intervention group · Children aged 1–8 years with moderate-to-severe atopic dermatitis | 2 g | 120 days | 26 |
| Clinical and microbiological outcomes of subgingival instrumentation supplemented with high-dose omega-3 polyunsaturated fatty acids in periodontal treatment - a randomized clinical trial 2023 · Test group (SRP plus fish oil) · Adults aged 22–70 with generalized stage III or IV periodontitis | 20 mL | 26 weeks | 24 |
| A Five-Ingredient Nutritional Supplement and Home-Based Resistance Exercise Improve Lean Mass and Strength in Free-Living Elderly 2020 · Muscle5 (M5) · Sedentary or low-active, free-living men aged 65 years or older, with normal to class 1/low-risk obesity and varying degrees of age-related muscle loss | 2.46 g | 12 weeks | 22 |
| Omega-3 Polyunsaturated Fatty Acids EPA and DHA as an Adjunct to Non-Surgical Treatment of Periodontitis: A Randomized Clinical Trial 2020 · Test group · Adults aged 22–70 with generalized stage III or IV periodontitis | 20 mL | 90 days | 20 |
| An adaptogenic role for omega-3 fatty acids in stress; a randomised placebo controlled double blind intervention study (pilot) [ISRCTN22569553] 2004 · Active (fish oil) · University staff aged 18–60 with moderate to high perceived stress | 2 g | 6 weeks | 16 |
| Obesity and Metabolic Disease Impair the Anabolic Response to Protein Supplementation and Resistance Exercise: A Retrospective Analysis of a Randomized Clinical Trial with Implications for Aging, Sarcopenic Obesity, and Weight Management 2024 · Muscle 5 (M5) · Men aged 66–91 years; older, sedentary or low-active participants, with the subgroup analysis including overweight or obese men with at least one additional metabolic-syndrome risk factor | 2.46 g | 12 weeks | 16 |
| Supplementation with Whey Protein, Omega-3 Fatty Acids and Polyphenols Combined with Electrical Muscle Stimulation Increases Muscle Strength in Elderly Adults with Limited Mobility: A Randomized Controlled Trial 2020 · WPI + BIO · Adults aged 60–90 with mobility limitations and gait speed below 1.5 m/s | 1.5 g | 12 weeks | 10 |
| Synergistic Effects of Probiotic and Omega-3 Supplementation with Ultra-Short Race Pace Training on Sprint Swimming Performance 2025 · Probiotics + Omega-3 + USRPT (PRO + OMEGA + USRPT) · Male competitive sprint swimmers with at least five years of competitive experience and no stated disease or medical condition | 1 g | 8 weeks | 10 |
| Effects of fish oil supplementation on platelet survival and ex vivo platelet function in hypercholesterolemic patients 1999 · fish oil group (T) · Patients with hypercholesterolemia, including hyperlipoproteinemia type IIa and IIb; age and sex not reported | 216 mg | 6 weeks | — |
| The Effect of Fish Oil, Vitamin D and Protein on URTI Incidence in Young Active People 2015 · supplementation · Young recreational athletes; age and sex not specified; healthy active population | 1.1 g | 16 weeks | — |
| Omega-3 and -6 fatty acid supplementation and sensory processing in toddlers with ASD symptomology born preterm: A randomized controlled trial 2017 · treatment group · Children aged 18–38 months, born at ≤29 weeks’ gestation and showing significant ASD symptoms | 706 mg | 90 days | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 group (n-3) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 3 g | 16 weeks | — |
| Myokine Circulating Levels in Postmenopausal Women with Overweight or Obesity: Effects of Resistance Training and/or DHA-Rich n-3 PUFA Supplementation 2025 · omega-3 + resistance training group (n-3+RT) · Postmenopausal women aged 55–70 with overweight or obesity (BMI 27.5–35 kg/m²) | 3 g | 16 weeks | — |
| Fish oil supplementation decreases serum soluble receptor activator of nuclear factor-kappa B ligand/osteoprotegerin ratio in female patients with rheumatoid arthritis 2010 · Fish oil group · Female patients with rheumatoid arthritis receiving conventional drugs | 1 g | 90 days | 40 |
| Effect of coadministration of omega-3 fatty acids with glimepiride on glycemic control, lipid profile, irisin, and sirtuin-1 in type 2 diabetes mellitus patients: a randomized controlled trial 2023 · omega-3 group · Adults aged 30–60 with type 2 diabetes for at least 2 years and HbA1c above 7% | 1 g | 12 weeks | 35 |
| Protective effect of fish oil supplementation on DNA damage induced by cigarette smoking 2013 · fish oil group · adult male cigarette smokers who had smoked at least 10 cigarettes per day for at least 2 years | 1 g | 90 days | 20 |
| Alimentary habits, physical activity, and Framingham global risk score in metabolic syndrome 2014 · DIS3 (dietary intervention and omega 3 fatty acid supplementation) · Men and women aged 30–60 years with metabolic syndrome | 1 g | 90 days | 20 |
| Alimentary habits, physical activity, and Framingham global risk score in metabolic syndrome 2014 · DIS3PE (dietary intervention, physical activity, and omega 3 fatty acid supplementation) · Men and women aged 30–60 years with metabolic syndrome | 1 g | 90 days | 17 |
| Postprandial triacylglycerolaemia: the effect of low-fat dietary treatment with and without fish oil supplementation 1996 · low-fat diet with fish oil supplementation · Healthy volunteers | 1 g | 16 weeks | 8 |
| Postprandial triacylglycerolaemia: the effect of low-fat dietary treatment with and without fish oil supplementation 1996 · full-fat diet with fish oil supplementation · Healthy volunteers | 1 g | 16 weeks | 8 |
| Dietary supplementation with gamma-linolenic acid or fish oil decreases T lymphocyte proliferation in healthy older humans 2001 · FO group · Healthy adults aged 55–75 years | 1 g | 12 weeks | — |
| Influence of dietary supplementation with long-chain n-3 or n-6 polyunsaturated fatty acids on blood inflammatory cell populations and functions and on plasma soluble adhesion molecules in healthy adults 2001 · FO · Healthy adults aged 55–75 years | 1 g | 12 weeks | — |
| DHA-rich oil modulates the cerebral haemodynamic response to cognitive tasks in healthy young adults: a near IR spectroscopy pilot study 2012 · DHA-rich fish oil · Healthy young adults | 1 g | 12 weeks | — |
| DHA-rich oil modulates the cerebral haemodynamic response to cognitive tasks in healthy young adults: a near IR spectroscopy pilot study 2012 · EPA-rich fish oil · Healthy young adults | 1 g | 12 weeks | — |
| Docosahexaenoic acid-rich fish oil modulates the cerebral hemodynamic response to cognitive tasks in healthy young adults 2012 · 1 g fish oil group · Healthy adults aged 18–29 years | 1 g | 12 weeks | — |
| Untitled fish oil group · female patients with rheumatoid arthritis | 1 g | 90 days | — |
| Supplementation of Catfish (Clarias gariepinus) Oil Enriched with Omega-3 Soft Capsule Improves Oxidative Stress and Cognitive Function in Elderly 2020 · CO with omega-3 (catfish oil enriched with omega-3) · Elderly people aged over 60 years with dyslipidemia | 1 g | 90 days | — |
| Effects of fish oil supplementation on biomarkers of vascular endothelial function in middle-aged and older adults: a randomized controlled trial 2026 · 1 g daily fish oil group · Community-based middle-aged and older adults receiving fish oil for primary cardiovascular prevention | 1 g | 12 weeks | — |
| Evaluating the Impact of Omega-3 Fatty Acid (Soloways(TM)) Supplementation on Lipid Profiles in Adults with PPARG Polymorphisms: A Randomized, Double-Blind, Placebo-Controlled Trial 2023 · omega-3 fatty acids group · Adults aged 40–75 with LDL-C levels of 70–190 mg/dL and low-to-moderate cardiovascular risk, including participants with and without PPARG polymorphisms | 2 g | 90 days | 51 |
| Fish oil amplifies the effect of propranolol in mild essential hypertension 1990 · Third subgroup: propranolol plus fish oil · Men with mild essential hypertension | 9 g | 12 weeks | 16 |
| Effects of fish oils on ex vivo B-cell responses of obese subjects upon BCR/TLR stimulation: a pilot study 2018 · FO concentrate · Obese men and women with BMI >30 | 4 g | 12 weeks | 12 |
| The effects of supplemental fish oil on blood pressure and morning cortisol in normotensive adults: a pilot study 2012 · Fish Oil (FO) · Adults, mean age 35±13 years, normotensive | 4 g | 6 weeks | — |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 0.7 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 700 mg | 8 weeks | — |
| Consumption of Fish Oil Providing Amounts of Eicosapentaenoic Acid and Docosahexaenoic Acid That Can Be Obtained from the Diet Reduces Blood Pressure in Adults with Systolic Hypertension: A Retrospective Analysis 2016 · Fish oil providing 1.8 g EPA+DHA/d · Healthy men and women; the reported subgroup with isolated systolic hypertension had n=31. | 1.8 g | 8 weeks | — |
| Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial 2018 · ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported | 6 g | 12 weeks | — |
| Effect of combined use of a low-carbohydrate, high-protein diet with omega-3 polyunsaturated fatty acid supplementation on glycemic control in newly diagnosed type 2 diabetes: a randomized, double-blind, parallel-controlled trial 2018 · LCHP+ω-3 diet group · Newly diagnosed participants with type 2 diabetes; age and sex not reported | 6 g | 12 weeks | — |
| Short report: the effect of fish oil on blood pressure and high-density lipoprotein-cholesterol levels in phase I of the Trials of Hypertension Prevention 1994 · fish oil group · Normotensive men and women aged 30–54 years | 6 g | 26 weeks | — |
| Maternal fish oil supplementation in lactation: effect on visual acuity and n-3 fatty acid content of infant erythrocytes 2004 · fish oil (FO) group · Danish lactating mothers with habitual fish intake below the 50th percentile of the Danish National Birth Cohort; their infants were assessed | 1.3 g | 120 days | 53 |
| Effects of marine-derived and plant-derived omega-3 polyunsaturated fatty acids on erythrocyte fatty acid composition in type 2 diabetic patients 2022 · FO (fish oil) group · Adults aged 18–70 with type 2 diabetes and dyslipidemia | 1.5 g | 26 weeks | 52 |
| Metabolic effects of krill oil are essentially similar to those of fish oil but at lower dose of EPA and DHA, in healthy volunteers 2011 · fish oil · Healthy adult men and women with normal or slightly elevated cholesterol and triglycerides | 1.8 g | 7 weeks | 40 |
| Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial 2013 · 900 mg/day EPA+DHA group · Healthy men and women aged 20–45 with low or no habitual oily-fish consumption | 900 mg | 150 days | 24 |
| Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial 2013 · 1800 mg/day EPA+DHA group · Healthy men and women aged 20–45 with low or no habitual oily-fish consumption | 1.8 g | 150 days | 24 |
| Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial 2013 · 600 mg/day EPA+DHA group · Healthy men and women aged 20–45 with low or no habitual oily-fish consumption | 600 mg | 150 days | 21 |
| Consumption of echium oil increases EPA and DPA in blood fractions more efficiently compared to linseed oil in humans 2016 · Fish oil (FO) · Normal-weight adults aged 20–69 years, women and men, without chronic disease reported | 1.9 g | 8 weeks | 20 |
| Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil 2011 · Fish oil rTAG · Healthy men aged 20–50 years | 1.68 g | 1 day | 12 |
| Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations--a comparative bioavailability study of fish oil vs. krill oil 2011 · Fish oil EE · Healthy men aged 20–50 years | 1.68 g | 1 day | 12 |
| Fish oil supplementation improves docosahexaenoic acid status of malnourished infants 2000 · fish oil supplemented children · Malnourished Pakistani children aged 8–30 months, mostly breast fed | 500 mg | 9 weeks | 10 |
| Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects 2003 · 0.94 g (EPA+DHA)/d · Healthy males aged 18–39 years | 940 mg | 12 weeks | — |
| Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects 2003 · 1.9 g (EPA+DHA)/d · Healthy males aged 18–39 years | 1.9 g | 12 weeks | — |
| Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: a multiple-dosing trial comparing 2 sources of n-3 fatty acid 2008 · 0.6 g fish oil/d · Firefighters exposed to cardiovascular disease risk factors; age and sex not stated | 600 mg | 12 weeks | — |
| Flaxseed oil and fish-oil capsule consumption alters human red blood cell n-3 fatty acid composition: a multiple-dosing trial comparing 2 sources of n-3 fatty acid 2008 · 1.2 g fish oil/d · Firefighters exposed to cardiovascular disease risk factors; age and sex not stated | 1.2 g | 12 weeks | — |
| Krill oil supplementation increases plasma concentrations of eicosapentaenoic and docosahexaenoic acids in overweight and obese men and women 2009 · menhaden oil · overweight and obese men and women | 2 g | 4 weeks | — |
| Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation 2015 · Study 1: 600 mg/day EPA + DHA · Healthy adults aged 20–45 years with low or no habitual oily-fish consumption | 600 mg | 20 weeks | — |
| Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation 2015 · Study 1: 900 mg/day EPA + DHA · Healthy adults aged 20–45 years with low or no habitual oily-fish consumption | 900 mg | 20 weeks | — |
| Red Blood Cell Docosapentaenoic Acid (DPA n-3) is Inversely Associated with Triglycerides and C-reactive Protein (CRP) in Healthy Adults and Dose-Dependently Increases Following n-3 Fatty Acid Supplementation 2015 · Study 1: 1800 mg/day EPA + DHA · Healthy adults aged 20–45 years with low or no habitual oily-fish consumption | 1.8 g | 20 weeks | — |
| The effect of fish oil supplementation on serum phospholipid fatty acids profile during pregnancy: A double blind randomized controlled trial 2017 · Fish oil supplementation group · Pregnant women aged 18–35 years | 1 g | — | — |
| Dose-dependent effects of fish oil on cardio-metabolic biomarkers in healthy middle-aged and elderly Chinese people: a double-blind randomized controlled trial 2018 · 0.62 g d-1 fish oil group · Healthy middle-aged and elderly Chinese people with insufficient dietary n-3PUFA intake | 620 mg | 12 weeks | — |
| Dose-dependent effects of fish oil on cardio-metabolic biomarkers in healthy middle-aged and elderly Chinese people: a double-blind randomized controlled trial 2018 · 1.24 g d-1 fish oil group · Healthy middle-aged and elderly Chinese people with insufficient dietary n-3PUFA intake | 1.24 g | 12 weeks | — |
| Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial 2018 · 400/200 EPA/DHA fish oil group · Patients with chronic heart failure and major depressive disorder, with a Hamilton Depression Scale score of at least 18; age and sex not specified | 2 g | 12 weeks | — |
| Effects of fish oil intervention on type 2 diabetes early risk novel biomarkers in healthy middle-aged and elderly adults: a double-blind randomized controlled trial 2025 · fish oil group 2 (FO2) · Healthy adults over 40 years old | 620 mg | 12 weeks | — |
| Effects of fish oil intervention on type 2 diabetes early risk novel biomarkers in healthy middle-aged and elderly adults: a double-blind randomized controlled trial 2025 · fish oil group 3 (FO3) · Healthy adults over 40 years old | 1.24 g | 12 weeks | — |
| Effects of 12-week supplementation of marine Omega-3 PUFA-based formulation Omega3Q10 in older adults with prehypertension and/or elevated blood cholesterol 2017 · Omega3Q10 treatment group · Adults aged at least 50 years with elevated blood pressure and/or elevated blood cholesterol | 1 g | 12 weeks | 48 |
| Fish-oil esters of plant sterols differ from vegetable-oil sterol esters in triglycerides lowering, carotenoid bioavailability and impact on plasminogen activator inhibitor-1 (PAI-1) concentrations in hypercholesterolemic subjects 2007 · PS-FO · Men and postmenopausal women aged 30–65 years with mildly overweight hypercholesterolemia | 9.6 g | 4 weeks | 21 |
| Untitled 2012 · ω-3 group · Children born at term, assessed in the cardiovascular substudy among those with birth weight below the 90th percentile | 500 mg | 1826 days | 187 |
| Fish-oil supplementation alters numbers of circulating endothelial progenitor cells and microparticles independently of eNOS genotype 2014 · fish-oil supplementation · Subjects at moderate risk of cardiovascular disease; age and sex not specified | 1.5 g | 8 weeks | 84 |
| Replication of a Gene-Diet Interaction at CD36, NOS3 and PPARG in Response to Omega-3 Fatty Acid Supplements on Blood Lipids: A Double-Blind Randomized Controlled Trial 2018 · fish oil group · Adults aged 35–80 years (women postmenopausal), with type 2 diabetes | 2 g | 180 days | 63 |
| Lipid extract from blue mussel (Mytilus edulis) improves glycemic traits in Chinese type 2 diabetic mellitus patients: a double-blind randomized controlled trial 2023 · fish oil (FO) group · Chinese adults with type 2 diabetes mellitus | 1.6 g | 60 days | 44 |
| Dietary n-3 polyunsaturated fatty acids alter the number, fatty acid profile and coagulatory activity of circulating and platelet-derived extracellular vesicles: a randomized, controlled crossover trial 2024 · fish oil · Adults aged 40–70 years with moderate cardiovascular disease risk, without diagnosed diseases | 1.9 g | 12 weeks | 40 |
| Lowering effects of fish oil supplementation on proinflammatory markers in hypertension: results from a randomized controlled trial 2020 · fish oil (FO) · Middle-aged/elderly adults with hypertension | 2 g | 90 days | 38 |
| Apolipoprotein E genotype status affects habitual human blood mononuclear cell gene expression and its response to fish oil intervention 2016 · Fish-oil supplementation · Adults carrying or not carrying the APOE4 genotype; ages and health conditions not specified | 1.8 g | 180 days | 23 |
| Serum metabolomics profiles in response to n-3 fatty acids in Chinese patients with type 2 diabetes: a double-blind randomised controlled trial 2016 · fish oil (FO) · Chinese adults aged 35–80 years with type 2 diabetes; men aged 35–80 and post-menopausal women up to age 80 | 2 g | 180 days | 20 |
| Dietary echium oil increases long-chain n-3 PUFAs, including docosapentaenoic acid, in blood fractions and alters biochemical markers for cardiovascular disease independently of age, sex, and metabolic syndrome 2014 · fish oil (FO; control) group · Normal-weight adults in age groups 20–35 and 49–69 years | 1.9 g | 8 weeks | 19 |
| High-quality fish oil has a more favourable effect than oxidised fish oil on intermediate-density lipoprotein and LDL subclasses: a randomised controlled trial 2017 · oxidised FO · Healthy human subjects; age and sex not specified | 1.6 g | 7 weeks | 18 |
| High-quality fish oil has a more favourable effect than oxidised fish oil on intermediate-density lipoprotein and LDL subclasses: a randomised controlled trial 2017 · high-quality FO · Healthy human subjects; age and sex not specified | 1.6 g | 7 weeks | 17 |
| Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation 2010 · 2 g/d fish oil · Overweight or obese adults; mean age 53 years; 36 males and 31 females overall | 2 g | 12 weeks | 16 |
| Lipid-lowering effect of polyunsaturated fatty acids in hemodialysis patients 2000 · fish oil · Hemodialysis patients; age and sex not reported | 1.5 g | 60 days | 15 |
| Interaction of low dose of fish oil and glucocorticoids on insulin sensitivity and lipolysis in healthy humans: A randomized controlled study 2016 · Fish oil subgroup · Healthy subjects; age and sex not reported | 840 mg | 3 weeks | 8 |
| Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients 2013 · supplemented group (SG) · Adults with colorectal cancer receiving chemotherapy | 2 g | 9 weeks | 6 |
| Influence of very low dietary intake of marine oil on some functional aspects of immune cells in healthy elderly people 2003 · marine oil group · healthy elderly people; age range and sex not specified | 600 mg | 6 weeks | — |
| Cardiac autonomic changes associated with fish oil vs soy oil supplementation in the elderly 2005 · fish oil group · Elderly nursing home residents | 2 g | 26 weeks | — |
| Can foods with added soya-protein or fish-oil reduce risk factors for coronary disease? A factorial randomised controlled trial 2004 · fish-oil factor · Middle-aged men and women with untreated elevated total cholesterol or blood pressure | 2 g | 5 weeks | — |
| Omega-3 fatty acid prevents heart rate variability reductions associated with particulate matter 2005 · fish oil · Nursing home residents older than 60 years in Mexico City | 2 g | 150 days | — |
| Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels 2008 · 2 g/d DHA-rich fish oil · Men and women, mean age 53 years, with fasting serum TAG ≥1.1 mmol/l and BMI >25 kg/m² | 2 g | 12 weeks | — |
| Independent and interactive effects of plant sterols and fish oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidaemic Indian adults 2009 · Control yoghurt drink and fish oil capsules · Adults aged 35–55 years with mild hypercholesterolaemia | 2 g | 4 weeks | — |
| Effects of weight loss and seafood consumption on inflammation parameters in young, overweight and obese European men and women during 8 weeks of energy restriction 2010 · fish oil capsules · Men and women aged 20–40 years with BMI 27.5–32.5 kg/m² from Iceland, Spain and Ireland | 1.3 g | 8 weeks | — |
| The effects of low dose n-3 fatty acids on serum lipid profiles and insulin resistance of the elderly: a randomized controlled clinical trial 2010 · intervention group · Elderly Iranian residents aged 65 or older | 1 g | 26 weeks | — |
| Docosahexaenoic acid-rich fish oil modulates the cerebral hemodynamic response to cognitive tasks in healthy young adults 2012 · 2 g fish oil group · Healthy adults aged 18–29 years | 2 g | 12 weeks | — |
| Low-dose fish oil supplementation increases serum adiponectin without affecting inflammatory markers in overweight subjects 2012 · fish oil group · Overweight subjects; age and sex not specified | 2 g | 6 weeks | — |
| Fish oil supplement alters markers of inflammatory and nutritional status in colorectal cancer patients 2012 · supplemented group (SG) · Patients with colorectal cancer undergoing chemotherapy; age and sex not reported | 2 g | 9 weeks | — |
| A new, microalgal DHA- and EPA-containing oil lowers triacylglycerols in adults with mild-to-moderate hypertriglyceridemia 2014 · FO · Adults with mild-to-moderate hypertriglyceridemia (TAG 150–499 mg/dL) | 2 g | 14 weeks | — |
| Reduced ex vivo stimulated IL-6 response in infants randomized to fish oil from 9 to 18 months, especially among PPARG2 and COX2 wild types 2015 · fish oil (FO) · Infants aged 9–18 months | 1.2 g | 274 days | — |
| Effect of vitamin B-12 and n-3 polyunsaturated fatty acids on plasma homocysteine, ferritin, C-reaction protein, and other cardiovascular risk factors: a randomized controlled trial 2015 · fish oil group · Eligible subjects; age, sex, and health condition not specified | 2 g | 8 weeks | — |
| Supplementation with omega-3 or omega-6 fatty acids attenuates platelet reactivity in postmenopausal women 2022 · Fish oil (omega-3) supplementation · Postmenopausal women aged 40–70 years, healthy or with type 2 diabetes | 2 g | 60 days | — |
| Effects of fish oil supplementation on biomarkers of vascular endothelial function in middle-aged and older adults: a randomized controlled trial 2026 · 2 g daily fish oil group · Community-based middle-aged and older adults receiving fish oil for primary cardiovascular prevention | 2 g | 12 weeks | — |
| Untitled Fish oil group · Adults aged 18 or older with end-stage renal disease receiving chronic hemodialysis and requiring a new synthetic AV-graft | 4 g | 1 year | 101 |
| The impact of fish oil and/or probiotics on serum fatty acids and the interaction with low-grade inflammation in pregnant women with overweight and obesity: secondary analysis of a randomised controlled trial 2024 · fish oil + placebo · Pregnant women with overweight or obesity, recruited in early pregnancy before 18 gestational weeks | 4.8 g | 150 days | 90 |
| Effects of Maternal Ω-3 Supplementation on Fatty Acids and on Visual and Cognitive Development 2015 · supplemented group (fish oil [FO]) · Pregnant women; supplementation continued during pregnancy and lactation | 400 mg | — | 56 |
| Effects of n-3 polyunsaturated fatty acid supplementation in pregnancy on maternal and fetal erythrocyte fatty acid composition 2004 · fish oil group · Pregnant women recruited during pregnancy; healthy full-term babies were assessed at birth | 4 g | — | 52 |
| Effects of marine-derived and plant-derived omega-3 polyunsaturated fatty acids on erythrocyte fatty acid composition in type 2 diabetic patients 2022 · LFO (mixed linseed oil and fish oil) group · Adults aged 18–70 with type 2 diabetes and dyslipidemia | 1.5 g | 26 weeks | 48 |
| Incorporation of eicosapentaenoic and docosahexaenoic acids into lipid pools when given as supplements providing doses equivalent to typical intakes of oily fish 2012 · 4-portions group · Men and women aged 20–80 years with low or no habitual oily-fish consumption and no specified chronic clinical condition | 4.5 g | 1 year | 42 |
| Randomized controlled trial examining the effects of fish oil and multivitamin supplementation on the incorporation of n-3 and n-6 fatty acids into red blood cells 2014 · Fish Oil, 6 g · Healthy men and women aged 50–70 years | 6 g | 16 weeks | 41 |
| Fish oil supplementation in pregnancy modifies neonatal allergen-specific immune responses and clinical outcomes in infants at high risk of atopy: a randomized, controlled trial 2003 · fish oil · Atopic pregnant women | 3.7 g | — | 40 |
| Dietary supplementation with seed oil from transgenic Camelina sativa induces similar increments in plasma and erythrocyte DHA and EPA to fish oil in healthy humans 2020 · Commercial blended fish oil (FO; fish oil plus cod liver oil) · Healthy men and women aged 20–74 years | 450 mg | 8 weeks | 31 |
| Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification: A sixteen-week randomized intervention trial 2023 · Ultimate Omega (UO) group · Healthy, normolipidemic adults aged 18–35 years; men and women | 5 g | 128 days | 30 |
| Comparative membrane incorporation of omega-3 fish oil triglyceride preparations differing by degree of re-esterification: A sixteen-week randomized intervention trial 2023 · Meg-3 (M3) group · Healthy, normolipidemic adults aged 18–35 years; men and women | 5 g | 128 days | 30 |
| Enhanced increase of omega-3 index in healthy individuals with response to 4-week n-3 fatty acid supplementation from krill oil versus fish oil 2013 · Fish oil · Healthy men and premenopausal, non-pregnant, non-nursing women aged 18–49 | 3 g | 4 weeks | 24 |
| Determinants of erythrocyte omega-3 fatty acid content in response to fish oil supplementation: a dose-response randomized controlled trial 2013 · 300 mg/day EPA+DHA group · Healthy men and women aged 20–45 with low or no habitual oily-fish consumption | 300 mg | 150 days | 23 |
| Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study 2015 · Treatment A Ethyl Ester (fish oil-EE) · Healthy adults aged 18–60 years, men and women; no stated disease | 6.89 g | 4 weeks | 22 |
| Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study 2015 · Treatment B Triglycerides (fish oil-TG) · Healthy adults aged 18–60 years, men and women; no stated disease | 6.87 g | 4 weeks | 22 |
| Equal bioavailability of omega-3 PUFA from Calanus oil, fish oil and krill oil: A 12-week randomized parallel study 2023 · FO group · Healthy volunteers; mean age 29.7 years; sex not specified | 248 mg | 12 weeks | 22 |
| Clinical Benefits of n-3 PUFA and ɤ-Linolenic Acid in Patients with Rheumatoid Arthritis 2017 · Group I (fish oil) · Women, mean age 63.1 years, with rheumatoid arthritis | 5 g | 12 weeks | 20 |
| Clinical Benefits of n-3 PUFA and ɤ-Linolenic Acid in Patients with Rheumatoid Arthritis 2017 · Group II (fish oil plus evening primrose oil) · Women, mean age 63.1 years, with rheumatoid arthritis | 2 g | 12 weeks | 20 |
| Microencapsulated Tuna Oil Results in Higher Absorption of DHA in Toddlers 2020 · fish oil group · Toddlers aged 1–4 years recruited from nurseries and daycare centres in Malaysia; healthy, with no stated diagnosed condition | 1 mL | 30 days | 15 |
| Microencapsulated Tuna Oil Results in Higher Absorption of DHA in Toddlers 2020 · ME formula 1 group · Toddlers aged 1–4 years recruited from nurseries and daycare centres in Malaysia; healthy, with no stated diagnosed condition | 2.2 g | 30 days | 15 |
| Microencapsulated Tuna Oil Results in Higher Absorption of DHA in Toddlers 2020 · ME formula 2 group · Toddlers aged 1–4 years recruited from nurseries and daycare centres in Malaysia; healthy, with no stated diagnosed condition | 3.3 g | 30 days | 15 |
| Krill Oil Has Different Effects on the Plasma Lipidome Compared with Fish Oil Following 30 Days of Supplementation in Healthy Women: A Randomized Controlled and Crossover Study 2020 · Fish oil (FO) supplementation · Healthy premenopausal women aged 18–50 years | 5 g | 30 days | 11 |
| Effect of docosahexaenoic acid-rich fish oil supplementation on human leukocyte function 2006 · fish oil supplementation · Adult male volunteers | 3 g | 60 days | 10 |
| Enhanced absorption of n-3 fatty acids from emulsified compared with encapsulated fish oil 2009 · Emulsified fish oil (EFO) · Healthy adults aged 18–60 years, with no reported current medical problems | 4 g | 1 day | 10 |
| Postprandial long-chain n-3 polyunsaturated fatty acid response to krill oil and fish oil consumption in healthy women: a randomised controlled, single-dose, crossover study 2018 · Fish oil (FO) · Healthy women aged 18–45 years | 5 g | 1 day | 10 |
| Comparison of the effects of linseed oil and different doses of fish oil on mononuclear cell function in healthy human subjects 2003 · 0.44 g (EPA+DHA)/d · Healthy males aged 18–39 years | 440 mg | 12 weeks | — |
| Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans 2004 · EPA · Healthy human subjects; age and sex not specified | 4.7 g | 4 weeks | — |
| Fish oil supplementation modulates immune function in healthy infants 2007 · cow's milk with fish oil · Healthy Danish infants aged 9–12 months | 3.4 mL | 90 days | — |
| Fish oil supplementation modulates immune function in healthy infants 2007 · infant formula with fish oil · Healthy Danish infants aged 9–12 months | 3.4 mL | 90 days | — |
| Effects of fish-oil supplementation on myocardial fatty acids in humans 2007 · fish oil for 7 days · Patients with low self-reported fish intake accepted for elective cardiac surgery involving cardiopulmonary bypass | 6 g | 7 days | — |
| Effects of fish-oil supplementation on myocardial fatty acids in humans 2007 · fish oil for 14 days · Patients with low self-reported fish intake accepted for elective cardiac surgery involving cardiopulmonary bypass | 6 g | 2 weeks | — |
| Effects of fish-oil supplementation on myocardial fatty acids in humans 2007 · fish oil for 21 days · Patients with low self-reported fish intake accepted for elective cardiac surgery involving cardiopulmonary bypass | 6 g | 3 weeks | — |
| Dose-dependent effects of fish oil on cardio-metabolic biomarkers in healthy middle-aged and elderly Chinese people: a double-blind randomized controlled trial 2018 · 0.31 g d-1 fish oil group · Healthy middle-aged and elderly Chinese people with insufficient dietary n-3PUFA intake | 310 mg | 12 weeks | — |
| A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults 2020 · SEDDS AquaCelle fish oil formulation · Healthy adults | 680 mg | 1 day | — |
| A self-emulsifying Omega-3 ethyl ester formulation (AquaCelle) significantly improves eicosapentaenoic and docosahexaenoic acid bioavailability in healthy adults 2020 · Unformulated fish oil EE control · Healthy adults | 680 mg | 1 day | — |
| Effects of Fish Oil on Biomarkers of Axonal Injury and Inflammation in American Football Players: A Placebo-Controlled Randomized Controlled Trial 2022 · treatment group · NCAA Division I American football athletes cleared to participate; sex and age range not reported | 3.5 g | 26 weeks | — |
| Effects of fish oil intervention on type 2 diabetes early risk novel biomarkers in healthy middle-aged and elderly adults: a double-blind randomized controlled trial 2025 · fish oil group 1 (FO1) · Healthy adults over 40 years old | 310 mg | 12 weeks | — |
| [Selenium concentration in erythrocytes of patients with rheumatoid arthritis. Clinical and laboratory chemistry infection markers during administration of selenium] 1997 · Placebo group · Adults with rheumatoid arthritis | 30 mg/kg | 90 days | — |
| Effects of fish oil supplementation on eicosanoid production in patients at higher risk for colorectal cancer 2019 · fish oil · Adults aged 40–80 with a past history of one or more colorectal adenomas | 2.52 g | 24 weeks | 70 |
| ApoE polymorphism and fish oil supplementation in subjects with an atherogenic lipoprotein phenotype 2000 · fish oil · Males aged 34 to 69 years with an atherogenic lipoprotein phenotype | 3 g | 6 weeks | 55 |
| Eicosapentaenoic acid and docosahexaenoic acid from fish oils: differential associations with lipid responses 2002 · fish-oil intervention · Mildly hypertriacylglycerolaemic men | 6 g | 6 weeks | 55 |
| Improvement in Glycolipid Metabolism Parameters After Supplementing Fish Oil-Derived Omega-3 Fatty Acids Is Associated with Gut Microbiota and Lipid Metabolites in Type 2 Diabetes Mellitus 2024 · fish oil group · Adults aged 18–70 with well-controlled type 2 diabetes mellitus | 3 g | 90 days | 55 |
| [Effects of ω-3 polyunsaturated fatty acids from different sources on glucolipid metabolism in type 2 diabetic patients with dyslipidemia] 2019 · fish oil (FO) · Adults with type 2 diabetes and dyslipidemia; mean age among completers 62.6 years | 3 g | 26 weeks | 54 |
| Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186 2008 · arm A (fish oil), step 1 · Adults aged 18 or older with HIV infection, taking antiretroviral therapy, and with hypertriglyceridemia | 6 g | 18 weeks | 50 |
| Fish-oil supplement has neutral effects on vascular and metabolic function but improves renal function in patients with Type 2 diabetes mellitus 2010 · fish-oil · People with type 2 diabetes mellitus without prior cardiovascular disease | 4 g | 12 weeks | 49 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 0 mg alpha-tocopheryl acetate (placebo) phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 15 g | 5 weeks | 48 |
| Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1 2003 · fish oil supplementation + dietary intervention · Elderly men at high risk for coronary heart disease | 2.4 g | 548 days | 47 |
| Supplementation with fish oil affects the association between very long-chain n-3 polyunsaturated fatty acids in serum non-esterified fatty acids and soluble vascular cell adhesion molecule-1 2003 · fish oil supplementation · Elderly men at high risk for coronary heart disease | 2.4 g | 548 days | 44 |
| Fatty acid saturation of the diet and plasma lipid concentrations, lipoprotein particle concentrations, and cholesterol efflux capacity 2002 · n-3 polyunsaturated fat diet · 41 adult women and men | 4 g | 5 weeks | 41 |
| Maternal fish oil supplementation in pregnancy reduces interleukin-13 levels in cord blood of infants at high risk of atopy 2003 · fish oil capsules · Atopic pregnant women at high risk of having infants with allergic disease | 3.7 g | — | 40 |
| Fish oil supplementation in pregnancy lowers F2-isoprostanes in neonates at high risk of atopy 2004 · fish oil · Pregnant atopic women, from 20 weeks’ gestation; their neonates were at high risk of allergy | 4 g | — | 40 |
| Short-Term, High-Dose Fish Oil Supplementation Increases the Production of Omega-3 Fatty Acid-Derived Mediators in Patients With Peripheral Artery Disease (the OMEGA-PAD I Trial) 2015 · Fish Oil · Adults aged 50 years and older, primarily men, with symptomatic lower-extremity peripheral artery disease and intermittent claudication | 4.4 g | 30 days | 40 |
| Effects of long-term ω-3 polyunsaturated fatty acid supplementation on paroxysmal atrial tachyarrhythmia burden in patients with implanted pacemakers: results from a prospective randomised study 2013 · Fish oil group · Adults aged 60 years or older with sinoatrial node disease and dual-chamber pacemakers | 6 g | 1 year | 39 |
| Fish Oil Supplements Lower Serum Lipids and Glucose in Correlation with a Reduction in Plasma Fibroblast Growth Factor 21 and Prostaglandin E2 in Nonalcoholic Fatty Liver Disease Associated with Hyperlipidemia: A Randomized Clinical Trial 2015 · fish oil group · Adults with nonalcoholic fatty liver disease and hyperlipidemia; ages and sex not restricted | 4 g | 90 days | 36 |
| An increase in plasma brain derived neurotrophic factor levels is related to n-3 polyunsaturated fatty acid efficacy in first episode schizophrenia: secondary outcome analysis of the OFFER randomized clinical trial 2019 · EPA + DHA group · Patients aged 16–35 with first-episode schizophrenia, drug-naive or early-treated | 2.2 g | 26 weeks | 36 |
| Comparison of effects of N-3 to N-6 fatty acids on serum level of lipoprotein(a) in patients with coronary artery disease 1995 · fish oil group · Hospitalized men with coronary artery disease | 12 g | 4 weeks | 35 |
| Mechanistic insights into the health benefits of fish-oil supplementation against fine particulate matter air pollution: a randomized controlled trial 2022 · fish oil group · Healthy college students aged 18 years or older; men and women; no diagnosed condition specified | 2.5 g | 120 days | 34 |
| Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants 1993 · fish-oil group · Recipients of first cadaveric kidney transplants treated with cyclosporine and prednisolone | 6 g | 1 year | 33 |
| Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia 2007 · CT-SO · HIV-infected patients receiving HAART with HAART-associated dyslipidemia | 3 g | 12 weeks | 32 |
| Dietary supplementation with a natural carotenoid mixture decreases oxidative stress 2003 · Fish oil · Healthy, free-living, nonsmoking adults | 4 g | 3 weeks | 31 |
| Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group 1995 · fish oil capsules · Patients with angiographically documented coronary heart disease and normal plasma lipid levels | 6 g | 852 days | 31 |
| Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia 1993 · combined pravastatin plus fish oil therapy · Patients with mixed hyperlipidemia; age and sex not specified | 6 g | 12 weeks | 31 |
| Evaluation of the effects of Neptune Krill Oil on the clinical course of hyperlipidemia 2004 · Group C · Patients with hyperlipidemia and blood cholesterol levels of 194–348 mg/dL; age and sex not stated | 3 g | 90 days | 30 |
| Concentrated fish oil ameliorates non-alcoholic fatty liver disease by regulating fibroblast growth factor 21-adiponectin axis 2022 · FO · Patients with NAFLD; mean age 55.9 ± 15.6 years; sex not stated | 3 g | 90 days | 30 |
| Phase II prospective randomized trial of a low-fat diet with fish oil supplementation in men undergoing radical prostatectomy 2011 · low-fat/fish oil group · Men with clinically localized prostate adenocarcinoma scheduled for radical prostatectomy | 5.5 g | 30 days | 29 |
| Effect of a low-fat fish oil diet on proinflammatory eicosanoids and cell-cycle progression score in men undergoing radical prostatectomy 2014 · Low-fat fish oil (LFFO) group · Men diagnosed with prostate cancer undergoing radical prostatectomy | 5 g | 30 days | 27 |
| Fish oil supplementation improves large arterial elasticity in overweight hypertensive patients 2008 · fish oil group · Overweight hypertensive patients | 3 g | 8 weeks | 26 |
| Effectiveness and tolerability of oral administration of low-dose salmon oil to HIV patients with HAART-associated dyslipidemia 2007 · SO-24 · HIV-infected patients receiving HAART with HAART-associated dyslipidemia | 3 g | 24 weeks | 26 |
| Fish oil in lupus nephritis: clinical findings and methodological implications 1993 · fish oil · People with confirmed systemic lupus and lupus nephritis; age and sex not stated | 15 g | 1 year | 26 |
| n-3 polyunsaturated fatty acid supplementation reduces insulin resistance in hepatitis C virus infected patients: a randomised controlled trial 2016 · n-3 PUFA · Patients with genotype 1 hepatitis C virus infection and HOMA-IR ≥2.5; age and sex not reported | 6 g | 12 weeks | 25 |
| Fish oil before cardiac surgery: neutrophil activation is unaffected but myocardial damage is moderated 2005 · fish oil · Patients undergoing cardiac surgery with cardiopulmonary bypass | 8 g | 6 weeks | 22 |
| Effects of omega-3 polyunsaturated fatty-acid supplementation on redox status in chronic renal failure patients with dyslipidemia 2010 · omega-3 group · Adults with chronic renal failure and dyslipidemia and/or hypertriglyceridemia or hypercholesterolemia; mean age 61 ± 14 years; 22 men and 18 women across the study | 2.1 g | 90 days | 20 |
| A Randomized Double-Blinded, Placebo-Controlled Trial Investigating the Effect of Fish Oil Supplementation on Gene Expression Related to Insulin Action, Blood Lipids, and Inflammation in Gestational Diabetes Mellitus-Fish Oil Supplementation and Gestational Diabetes 2018 · omega-3 · Women aged 18–40 with gestational diabetes mellitus and no prior history of diabetes | 2 g | 6 weeks | 20 |
| Effects of fish oil fatty acids on low density lipoprotein size, oxidizability, and uptake by macrophages 1995 · fish oil · Adults with treated hypertension; age and sex not reported | 4 g | 6 weeks | 20 |
| Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases 1997 · fish-oil concentrate, healthy subjects · Healthy subjects; age and sex not reported | 5 g | 3 weeks | 20 |
| Dysregulation of Subcutaneous White Adipose Tissue Inflammatory Environment Modelling in Non-Insulin Resistant Obesity and Responses to Omega-3 Fatty Acids - A Double Blind, Randomised Clinical Trial 2022 · Normal-weight fish-oil group · Adults aged 18–65 with normal weight (BMI 18.5–25 kg/m²), without diagnosed metabolic disease | 3 g | 12 weeks | 19 |
| Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil 1997 · fish oil (F) · renal transplant recipients with persistent hypercholesterolaemia and stable graft function | 6 g | 90 days | 18 |
| Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation 2010 · 4 g/d fish oil · Overweight or obese adults; mean age 53 years; 36 males and 31 females overall | 4 g | 12 weeks | 17 |
| Dose-dependent increases in heart rate variability and arterial compliance in overweight and obese adults with DHA-rich fish oil supplementation 2010 · 6 g/d fish oil · Overweight or obese adults; mean age 53 years; 36 males and 31 females overall | 6 g | 12 weeks | 17 |
| Dysregulation of Subcutaneous White Adipose Tissue Inflammatory Environment Modelling in Non-Insulin Resistant Obesity and Responses to Omega-3 Fatty Acids - A Double Blind, Randomised Clinical Trial 2022 · Obese fish-oil group · Adults aged 18–65 with obesity (BMI 30–40 kg/m²), without diagnosed metabolic disease | 3 g | 12 weeks | 17 |
| Effect of combined supplementation of fish oil with garlic pearls on the serum lipid profile in hypercholesterolemic subjects 2005 · Combined fish oil and garlic pearls group · Adults aged 30–60 with hypercholesterolemia and total cholesterol above 220 mg/dl | 600 mg | 60 days | 16 |
| Untitled 2012 · Fish oil (FO) group · Healthy nonsmoking adults aged 50–72 years without the listed heart, lung or metabolic conditions | 3 g | 4 weeks | 16 |
| Fish oil supplementation alters the plasma lipidomic profile and increases long-chain PUFAs of phospholipids and triglycerides in healthy subjects 2012 · fish oil (FO) group · Healthy men and women aged 18–50 years | 8 g | 7 weeks | 16 |
| High-fat meals rich in EPA plus DHA compared with DHA only have differential effects on postprandial lipemia and plasma 8-isoprostane F2α concentrations relative to a control high-oleic acid meal: a randomized controlled trial 2014 · FO meal (high n−3 PUFA, EPA + DHA) · Healthy, nonsmoking men aged 35–70 years with plasma triacylglycerol concentrations >1.2 mmol/L | 6.7 g | 1 day | 16 |
| Anti-inflammatory effect of combining fish oil and evening primrose oil supplementation on breast cancer patients undergoing chemotherapy: a randomized placebo-controlled trial 2023 · intervention group · Postmenopausal women aged 45–70 with stage IIa–IIIa breast cancer receiving adjuvant chemotherapy | 1 g | 12 weeks | 16 |
| Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects 2007 · 4 g/day tuna oil · Adults with hyperlipidaemia on stable statin therapy and persistently elevated plasma triglycerides | 4 g | 26 weeks | 15 |
| Dose-dependent effects of docosahexaenoic acid supplementation on blood lipids in statin-treated hyperlipidaemic subjects 2007 · 8 g/day tuna oil · Adults with hyperlipidaemia on stable statin therapy and persistently elevated plasma triglycerides | 8 g | 26 weeks | 15 |
| Hypocaloric diet associated with the consumption of jam enriched with microencapsulated fish oil decreases insulin resistance 2014 · microencapsulated fish oil group · adult women with metabolic syndrome | 3 g | 90 days | 15 |
| Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas 1994 · 2.5 g/day fish oil group (subsequent 6-month study) · Patients with polyps; age and sex not specified | 2.5 g | 26 weeks | 15 |
| Supplementation with n-3 fatty acids reduces triglycerides but increases PAI-1 in non-insulin-dependent diabetes mellitus 1992 · MaxEPA · 14 patients with non-insulin-dependent diabetes mellitus | 10 g | 8 weeks | 14 |
| A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease 2014 · ω-3 (fish oil concentrate) · Adults aged 55 years or older with probable Alzheimer’s disease | 3 g | 1 year | 13 |
| Renal effects of dietary supplementation with fish oil in cyclosporine-treated liver transplant recipients 1995 · fish oil group · Stable cyclosporine-treated liver transplant recipients; age and sex not reported | 12 g | 60 days | 13 |
| Effect of extra-virgin olive oil and fish-oil supplementation on plasma lipids and susceptibility of low-density lipoprotein to oxidative alteration in free-living spanish male patients with peripheral vascular disease 1999 · group OF · Male patients with peripheral vascular disease; age range not stated | 16 g | 90 days | 12 |
| A mixed Australian fish diet and fish-oil supplementation: impact on the plasma lipid profile of healthy men 1990 · fish-based meal supplemented with fish oil · healthy men; age not reported | 5 g | 6 weeks | 12 |
| Postprandial lipoprotein lipase, insulin and gastric inhibitory polypeptide responses to test meals of different fatty acid composition: comparison of saturated, n-6 and n-3 polyunsaturated fatty acids 1994 · Fish oil meal · Male volunteers, mean age 22.5 years, selected from a university student population | 40 g | 1 day | 12 |
| Moderate intake of n-3 fatty acids for 2 months has no detrimental effect on glucose metabolism and could ameliorate the lipid profile in type 2 diabetic men. Results of a controlled study 1998 · fish oil · men with type 2 diabetes and elevated plasma triacylglycerols | 6 g | 60 days | 12 |
| The effects of dietary supplementation with fish oil on renal function in cyclosporine-treated renal transplant recipients 1990 · fish oil · Stable cyclosporine-treated renal transplant recipients, at least nine months after grafting; ages and sex not reported | 6 g | 90 days | 11 |
| Polyunsaturated fatty acids of the n-6 and n-3 series: effects on postprandial lipid and apolipoprotein levels in healthy men 1994 · fish oil meal · Men with normal health, average age 22.4 years | 40 g | 1 day | 11 |
| Effect of dietary fish oil on blood levels of free fatty acids, ketone bodies and triacylglycerol in humans 1994 · fish oil · Healthy adults aged 21–23 years with normal liver function tests | 30 g | 7 days | 11 |
| Alteration of baroreflex control of forearm vascular resistance by dietary fatty acids 1990 · fish oil · Normotensive humans; age and sex not reported | 4.5 mL | 4 weeks | 10 |
| Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: a preliminary 1H MRS study 2016 · low-dose group · Male and female adolescents aged 8–24 years with major depressive disorder and residual depressive symptoms despite SSRI treatment | 2.4 g | 10 weeks | 10 |
| Effects of fish oil supplementation on prefrontal metabolite concentrations in adolescents with major depressive disorder: a preliminary 1H MRS study 2016 · high-dose group · Male and female adolescents aged 8–24 years with major depressive disorder and residual depressive symptoms despite SSRI treatment | 16.2 g | 10 weeks | 10 |
| Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 1994 · A: uncoated Purepa · Adults with Crohn's disease in remission; age and sex not reported | 4.5 g | 6 weeks | 10 |
| Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 1994 · B: Purepa coated, pH 5.5 · Adults with Crohn's disease in remission; age and sex not reported | 4.5 g | 6 weeks | 10 |
| Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 1994 · C: Purepa coated, pH 5.5, 60 min time release · Adults with Crohn's disease in remission; age and sex not reported | 4.5 g | 6 weeks | 10 |
| Effects of new fish oil derivative on fatty acid phospholipid-membrane pattern in a group of Crohn's disease patients 1994 · D: Purepa coated, pH 6.9 · Adults with Crohn's disease in remission; age and sex not reported | 4.5 g | 6 weeks | 10 |
| Effect of pravastatin and omega-3 fatty acids on plasma lipids and lipoproteins in patients with combined hyperlipidemia 1993 · fish oil · Patients with mixed hyperlipidemia; age and sex not specified | 6 g | 6 weeks | 10 |
| Dietary supplementation with n-3 fatty acids increases gluconeogenesis from glycerol but not hepatic glucose production in patients with non-insulin-dependent diabetes mellitus 1995 · n-3 fatty acid supplementation · Nine obese patients with non-insulin-dependent diabetes mellitus | 12 g | 6 weeks | 9 |
| Long-chain n-3 polyunsaturated fatty acid incorporation into human atrium following fish oil supplementation 2006 · treatment group · Volunteers preparing for coronary bypass surgery; age and sex not reported | 6 g | 6 weeks | 8 |
| Effects of DHA-rich fish oil supplementation on lymphocyte function before and after a marathon race 2013 · FO group · Marathon runners; age and sex not stated | 3 g | 60 days | 8 |
| Dietary omega-3 fatty acids lower levels of platelet-derived growth factor mRNA in human mononuclear cells 1993 · omega-3 fatty acid fish oil concentrate group · healthy male volunteers | 7 g | 6 weeks | 7 |
| Assessing the Potential of an Enzymatically Liberated Salmon Oil to Support Immune Health Recovery from Acute SARS-CoV-2 Infection via Change in the Expression of Cytokine, Chemokine and Interferon-Related Genes 2024 · OmeGo plus best standard of care (BSC) · Adults aged 18–75 with confirmed mild to moderate COVID-19 infection | 4 g | 4 weeks | 6 |
| Dietary supplementation with eicosapentaenoic acid, but not with other long-chain n-3 or n-6 polyunsaturated fatty acids, decreases natural killer cell activity in healthy subjects aged >55 y 2001 · Fish oil group · Healthy adults aged 55–75 years | 720 mg | 12 weeks | — |
| Short-term fish oil supplementation improved innate immunity, but increased ex vivo oxidation of LDL in man--a pilot study 2001 · fish oil · 10 healthy adult volunteers; age range and sex not reported | 25 g | 30 days | — |
| Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity 2002 · Fish oil · Men with visceral obesity, dyslipidaemia and insulin resistance; mean age 53 years | 4 g | 6 weeks | — |
| Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity 2002 · Atorvastatin plus fish oil · Men with visceral obesity, dyslipidaemia and insulin resistance; mean age 53 years | 4 g | 6 weeks | — |
| Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia 2002 · fish oils · Viscerally obese, insulin-resistant men with dyslipidemia | 4 g | — | — |
| Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia 2002 · atorvastatin and fish oils · Viscerally obese, insulin-resistant men with dyslipidemia | 4 g | — | — |
| Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity 2003 · fish oil capsules · Dyslipidemic, viscerally obese men | 4 g | 6 weeks | — |
| Plasma lipid levels and platelet and neutrophil function in patients with vascular disease following fish oil and olive oil supplementation 1992 · fish oil · Adults with symptomatic, angiographically demonstrated peripheral vascular disease; sex and age not reported | 15 g | 4 weeks | — |
| Dietary fish oil decreases C-reactive protein, interleukin-6, and triacylglycerol to HDL-cholesterol ratio in postmenopausal women on HRT 2003 · HFO · Healthy postmenopausal women taking HRT | 14 g | 5 weeks | — |
| Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients 1992 · fish oil (Maxepa) · Cardiac transplant recipients with hyperlipidemia, defined by serum total cholesterol > 6.5 or triglycerides > 2.8 mmol/L, or both; age and sex not reported | 10 g | 90 days | — |
| Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians 2004 · Moderate n-6 PUFA diet plus fish oil · Indian Asian men; age and health condition not specified | 4 g | 6 weeks | — |
| Increased n-6 polyunsaturated fatty acids do not attenuate the effects of long-chain n-3 polyunsaturated fatty acids on insulin sensitivity or triacylglycerol reduction in Indian Asians 2004 · High n-6 PUFA diet plus fish oil · Indian Asian men; age and health condition not specified | 4 g | 6 weeks | — |
| Docosahexaenoic and eicosapentaenoic acids in plasma phospholipids are divergently associated with high density lipoprotein in humans 1992 · fish oil group · men and women; ages and health status not stated | 6 g | 10 weeks | — |
| Circulating triacylglycerol and apoE levels in response to EPA and docosahexaenoic acid supplementation in adult human subjects 2004 · EPA-rich oil · normolipidaemic adult subjects | 4.8 g | 4 weeks | — |
| Reduced effect on apoptosis of 4-hydroxyhexenal and oxidized LDL enriched with n-3 fatty acids from postmenopausal women 2005 · high dose HFO · healthy postmenopausal women | 14 g | 5 weeks | — |
| Can foods with added soya-protein or fish-oil reduce risk factors for coronary disease? A factorial randomised controlled trial 2004 · fish-oil plus soya-protein factor · Middle-aged men and women with untreated elevated total cholesterol or blood pressure | 2 g | 5 weeks | — |
| Black currant seed oil and fish oil supplements differ in their effects on fatty acid profiles of plasma lipids, and concentrations of serum total and lipoprotein lipids, plasma glucose and insulin 2005 · fish oil · healthy females; age not reported | 2.8 g | 4 weeks | — |
| Fish oil supplementation of lactating mothers affects cytokine production in 2 1/2-year-old children 2005 · fish oil group · Lactating Danish mothers with fish intake below the population median | 4.5 g | 120 days | — |
| Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity 2006 · Fish oils without atorvastatin · Obese men with dyslipidemia | 4 g | 6 weeks | — |
| Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity 2006 · Fish oils with atorvastatin · Obese men with dyslipidemia | 4 g | 6 weeks | — |
| Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols 2006 · fish oil · Moderately overweight, hyperlipidemic adults; age and sex not specified | 5.4 g | 4 weeks | — |
| n-3 Fatty acid supplementation and regular moderate exercise: differential effects of a combined intervention on neutrophil function 2007 · DHA-rich fish oil; usual physical activity · Volunteers with risk factors for cardiovascular disease; age and sex not specified | 6 g | 12 weeks | — |
| n-3 Fatty acid supplementation and regular moderate exercise: differential effects of a combined intervention on neutrophil function 2007 · DHA-rich fish oil; regular exercise · Volunteers with risk factors for cardiovascular disease; age and sex not specified | 6 g | 12 weeks | — |
| Maternal fish oil supplementation in pregnancy modifies neonatal leukotriene production by cord-blood-derived neutrophils 2007 · fish oil · Pregnant women with allergic disease | 3.7 g | 20 weeks | — |
| The effects of fish oil and high or low linoleic acid intake on fatty acid composition of human peripheral blood mononuclear cells 2008 · FO+S/B group · Healthy young men | 4.4 mL | 8 weeks | — |
| The effects of fish oil and high or low linoleic acid intake on fatty acid composition of human peripheral blood mononuclear cells 2008 · FO+R/K group · Healthy young men | 4.4 mL | 8 weeks | — |
| Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels 2008 · 4 g/d DHA-rich fish oil · Men and women, mean age 53 years, with fasting serum TAG ≥1.1 mmol/l and BMI >25 kg/m² | 4 g | 12 weeks | — |
| Dose-dependent effects of docosahexaenoic acid-rich fish oil on erythrocyte docosahexaenoic acid and blood lipid levels 2008 · 6 g/d DHA-rich fish oil · Men and women, mean age 53 years, with fasting serum TAG ≥1.1 mmol/l and BMI >25 kg/m² | 6 g | 12 weeks | — |
| Comparison of the effects of fish and fish-oil capsules on the n 3 fatty acid content of blood cells and plasma phospholipids 2007 · fish-oil capsule group · Healthy premenopausal female volunteers | 485 mg | 16 weeks | — |
| Influence of moderate energy restriction and seafood consumption on bone turnover in overweight young adults 2008 · fish-oil capsules · Overweight men and women aged 20–40 years with BMI 27.5–32.5 | 3 g | 8 weeks | — |
| Identification of potential serum biomarkers of inflammation and lipid modulation that are altered by fish oil supplementation in healthy volunteers 2008 · fish oil · healthy volunteers | 3.5 g | 6 weeks | — |
| Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men 2008 · FO+R/K group · Healthy men | 5 mL | 8 weeks | — |
| Fish oil in combination with high or low intakes of linoleic acid lowers plasma triacylglycerols but does not affect other cardiovascular risk markers in healthy men 2008 · FO+S/B group · Healthy men | 5 mL | 8 weeks | — |
| The effect of fish oil supplementation on heart rate in healthy Danish infants 2008 · Fish oil with cow's milk · Healthy Danish infants aged 9–12 months | 3.4 mL | 90 days | — |
| The effect of fish oil supplementation on heart rate in healthy Danish infants 2008 · Fish oil with infant formula · Healthy Danish infants aged 9–12 months | 3.4 mL | 90 days | — |
| Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men 2009 · fish oil with high linoleic acid intake · healthy men | 5 mL | 8 weeks | — |
| Reduced ex vivo interleukin-6 production by dietary fish oil is not modified by linoleic acid intake in healthy men 2009 · fish oil with low linoleic acid intake · healthy men | 5 mL | 8 weeks | — |
| Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity 2010 · fish-oil supplementation · abdominally obese men | 4 g | 6 weeks | — |
| Effects of atorvastatin and n-3 fatty acid supplementation on VLDL apolipoprotein C-III kinetics in men with abdominal obesity 2010 · combination treatment (atorvastatin and fish oils) · abdominally obese men | 4 g | 6 weeks | — |
| Nitric oxide enhancement and blood pressure decrease in patients with metabolic syndrome using soy protein or fish oil 2010 · third group · Women with metabolic syndrome | 3 g | 90 days | — |
| Effect of fish oil supplementation on serum triglycerides, LDL cholesterol and LDL subfractions in hypertriglyceridemic adults 2013 · 4 g/d EPA + DHA · Adults with hypertriglyceridemia | 4 g | 12 weeks | — |
| Effects of fish oil on serum lipids in men during a controlled feeding trial 1990 · 5 g FO group · Healthy male college students | 5 g | 5 weeks | — |
| Effects of fish oil on serum lipids in men during a controlled feeding trial 1990 · 20 g FO group · Healthy male college students | 20 g | 5 weeks | — |
| Effects of fish oil supplements in NIDDM subjects. Controlled study 1990 · MaxEPA · NIDDM outpatients; mean age 55.9 years (SD 11.5); sex not reported | 10 g | 6 weeks | — |
| Effects of two types of fish oil supplements on serum lipids and plasma phospholipid fatty acids in coronary artery disease 1990 · triglyceride group · Adults with coronary artery disease | 6 g | 26 weeks | — |
| Effects of two types of fish oil supplements on serum lipids and plasma phospholipid fatty acids in coronary artery disease 1990 · ethyl ester group · Adults with coronary artery disease | 7 g | 26 weeks | — |
| Effects of fish-oil ingestion on cardiovascular risk factors in hyperlipidemic subjects in Israel: a randomized, double-blind crossover study 1990 · fish-oil supplement · 27 hyperlipidemic subjects; age and sex not specified | 15 g | — | — |
| Fish oil supplementation augments post-exercise immune function in young males 2012 · fish oil · young adult males undergoing endurance exercise; no condition stated | 3 g | 6 weeks | — |
| Untitled Group 1 (fish oil with NCEP-TLC controlled diet) · Adults aged 18–60, men and women with HIV taking a stable protease-inhibitor antiretroviral regimen and elevated fasting triglycerides | 4 g | 8 weeks | — |
| Effect of fish oil on lipoproteins, lecithin:cholesterol acyltransferase, and lipid transfer protein activity in humans 1990 · fish-oil group · Men with mild hypercholesterolemia; age not reported | 3.8 g | 6 weeks | — |
| Fish-oil concentrate: effects on variables related to cardiovascular disease 1990 · fish-oil concentrate group · Healthy men aged 35–45 years | 14 g | 6 weeks | — |
| High-dose eicosapentaenoic acid and docosahexaenoic acid supplementation reduces bone resorption in postmenopausal breast cancer survivors on aromatase inhibitors: a pilot study 2014 · EPA and DHA / fish oil group · Postmenopausal breast cancer survivors receiving aromatase inhibitor therapy | 4 g | 90 days | — |
| The effects of short-term fish oil supplementation on pulmonary function and airway inflammation following a high-fat meal 2014 · fish oil group · Men aged 22 ± 2 years without asthma | 3 g | 3 weeks | — |
| A double-blind randomized trial of fish oil to lower triglycerides and improve cardiometabolic risk in adolescents 2014 · fish oil · Adolescents aged 10–17 years with elevated triglycerides (≥150 and <750 mg/dL on two occasions) and LDL cholesterol <160 mg/dL | 4 g | 8 weeks | — |
| Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects 2015 · Formulation 1 (F1), short-term parallel study · Healthy participants | 4 g | 4 weeks | — |
| Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects 2015 · Formulation 2 (F2), short-term parallel study · Healthy participants | 4 g | 4 weeks | — |
| Bioequivalence of n-3 fatty acids from microencapsulated fish oil formulations in human subjects 2015 · Fish oil gel capsules (FOGC), short-term parallel study · Healthy participants | 4 g | 4 weeks | — |
| Effect of vitamin B-12 and n-3 polyunsaturated fatty acids on plasma homocysteine, ferritin, C-reaction protein, and other cardiovascular risk factors: a randomized controlled trial 2015 · vitamin B-12+fish oil group · Eligible subjects; age, sex, and health condition not specified | 2 g | 8 weeks | — |
| Fish oil supplementation from 9 to 18 months of age affects the insulin-like growth factor axis in a sex-specific manner in Danish infants 2016 · Fish oil group · Danish infants aged 9 to 18 months | 5 mL | 274 days | — |
| Specialized proresolving lipid mediators in patients with coronary artery disease and their potential for clot remodeling 2016 · Lovaza treatment · Patients with stable coronary artery disease; age and sex not specified | 3.36 g | 1 year | — |
| Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n-3 polyunsaturated fatty acids in a randomized controlled trial 2016 · n-3 PUFA-rich fish oil, normal-weight subjects · Normal-weight subjects; age and sex not reported | 3 g | 90 days | — |
| Impairment of lysophospholipid metabolism in obesity: altered plasma profile and desensitization to the modulatory properties of n-3 polyunsaturated fatty acids in a randomized controlled trial 2016 · n-3 PUFA-rich fish oil, obese subjects · Obese subjects; age and sex not reported | 3 g | 90 days | — |
| Effects of DHA-enriched fish oil on monocyte/macrophage activation marker sCD163, asymmetric dimethyl arginine, and insulin resistance in type 2 diabetic patients 2016 · DHA-enriched fish oil group · Adults aged 30–70 years with type 2 diabetes | 2.4 g | 8 weeks | — |
| DHA-enriched fish oil upregulates cyclin-dependent kinase inhibitor 2A (P16(INK)) expression and downregulates telomerase activity without modulating effects of PPARγ Pro12Ala polymorphism in type 2 diabetic patients: A randomized, double-blind, placebo-controlled clinical trial 2018 · DHA-enriched fish oil group · Adults aged 30–70 with type 2 diabetes and genotyped PPARγ Pro12Ala polymorphism | 2.4 g | 8 weeks | — |
| The benefits of ω-3 supplementation depend on adiponectin basal level and adiponectin increase after the supplementation: A randomized clinical trial 2017 · ω-3 · Adults of both sexes, mean age 52 years, with at least one cardiovascular risk factor | 3 g | 60 days | — |
| Arabinoxylan oligosaccharides and polyunsaturated fatty acid effects on gut microbiota and metabolic markers in overweight individuals with signs of metabolic syndrome: A randomized cross-over trial 2020 · PUFA intervention · Overweight individuals with indices of metabolic syndrome | 3.6 g | 4 weeks | — |
| Cardiovascular Benefits of Fish-Oil Supplementation Against Fine Particulate Air Pollution in China 2019 · intervention group · Healthy young adult college students in Shanghai, China; age and sex not specified | 2.5 g | 120 days | — |
| Differential plasma postprandial lipidomic responses to krill oil and fish oil supplementations in women: A randomized crossover study 2019 · fish oil supplementation · Healthy women aged 18–45 years | 5 g | 1 day | — |
| Alleviated systemic oxidative stress effects of combined atmospheric oxidant capacity by fish oil supplementation: A randomized, double-blinded, placebo-controlled trial 2019 · fish-oil group · young adults in Shanghai, China | 2.5 g | 60 days | — |
| Effects of DHA-enriched fish oil on gene expression levels of p53 and NF-κB and PPAR-γ activity in PBMCs of patients with T2DM: A randomized, double-blind, clinical trial 2020 · DHA-rich fish oil · Patients aged 30–70 years with type 2 diabetes mellitus | 2.4 g | 8 weeks | — |
| Protective effects of dietary fish-oil supplementation on skin inflammatory and oxidative stress biomarkers induced by fine particulate air pollution: a pilot randomized, double-blind, placebo-controlled trial 2021 · fish oil group · Healthy young adults; age range and sex not reported | 2.5 g | 120 days | — |
| Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids. A randomised cross-over study 2021 · fish oil (FO) · healthy adults | 6 g | 1 day | — |
| Effects of fish oil supplementation on biomarkers of vascular endothelial function in middle-aged and older adults: a randomized controlled trial 2026 · 4 g daily fish oil group · Community-based middle-aged and older adults receiving fish oil for primary cardiovascular prevention | 4 g | 12 weeks | — |
| A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM 1995 · 9 g of fish oil · Adults aged 53.9 ± 7.0 years with NIDDM and hyperlipidemia; men and women | 9 g | 12 weeks | — |
| A comparison of fish oil or corn oil supplements in hyperlipidemic subjects with NIDDM 1995 · 18 g of fish oil · Adults aged 53.9 ± 7.0 years with NIDDM and hyperlipidemia; men and women | 18 g | 12 weeks | — |
| Effects of a new fish oil concentrate on plasma lipids and lipoproteins in patients with hypertriglyceridaemia 1994 · K-85 · Men and women aged 18–70 years with primary hypertriglyceridaemia | 4 g | 14 weeks | — |
| Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas 1994 · 2.5 g/day fish oil group (30-day study) · Patients with sporadic colonic adenomas; age and sex not specified | 2.5 g | 30 days | — |
| Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas 1994 · 5.1 g/day fish oil group (30-day study) · Patients with sporadic colonic adenomas; age and sex not specified | 5.1 g | 30 days | — |
| Effects of different doses of fish oil on rectal cell proliferation in patients with sporadic colonic adenomas 1994 · 7.7 g/day fish oil group (30-day study) · Patients with sporadic colonic adenomas; age and sex not specified | 7.7 g | 30 days | — |
| Fish oil decreases serum homocysteine in hyperlipemic men 1993 · fish oil supplement · Men with type IIa or IIb lipoproteinemia or hypertriglyceridemia | 12 g | 3 weeks | — |
| Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa) 1993 · K-85 (fish oil ethyl ester) alone · Patients with familial hypercholesterolemia (type IIa) | 5.7 g | — | — |
| Inhibition of exercise-induced shortening of bleeding time by fish oil in familial hypercholesterolemia (type IIa) 1993 · K-85 (fish oil ethyl ester) combined with lovastatin · Patients with familial hypercholesterolemia (type IIa) | 5.7 g | — | — |
| Decreased platelet activity without change in fibrinolytic activity after low dosages of fish oil 1993 · Fish oil in gelatine capsules · Healthy adult male volunteers | 350 mg | 6 weeks | — |
| Decreased platelet activity without change in fibrinolytic activity after low dosages of fish oil 1993 · Microencapsulated fish oil · Healthy adult male volunteers | 350 mg | 6 weeks | — |
| Effects of fish oil supplementation in the third trimester of pregnancy on prostacyclin and thromboxane production 1993 · fish oil · Women in the 30th week of pregnancy | 2.7 g | 7 weeks | — |
| [Long-term effects of low dosage fish oil on serum lipids and lipoproteins] 1993 · fish oil · Patients with normal or moderately elevated serum lipids | 9 g | 1 year | — |
| Effect of three sources of long-chain fatty acids on the plasma fatty acid profile, plasma prostaglandin E2 concentrations, and pruritus symptoms in hemodialysis patients 1996 · fish oil group (FO group) · Hemodialysis patients with chronic renal failure and a history of pruritus symptoms | 6 g | 8 weeks | — |
| Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans 1996 · Fish oil concentrate (FOC) · Normolipidemic subjects; age and sex not reported | 3 g | 3 weeks | — |
| The triglyceride lowering effect of fish oils is affected by fish consumption 1996 · fish oil capsules · Portuguese patients with hypertriglyceridaemia and mixed hyperlipidaemia; ages and sex not reported | 3.6 g | 60 days | — |
| Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men 1997 · 12 g fish oil/d providing 3.6 g n-3 fatty acids/d · Men with moderate hypercholesterolemia | 12 g | 12 weeks | — |
| Does vegetable oil attenuate the beneficial effects of fish oil in reducing risk factors for cardiovascular disease? 1997 · fish oil, 9 g/d · Human subjects; age, sex, and health status not specified | 9 g | — | — |
| Does vegetable oil attenuate the beneficial effects of fish oil in reducing risk factors for cardiovascular disease? 1997 · fish oil, 15 g/d · Human subjects; age, sex, and health status not specified | 15 g | — | — |
| Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study 1997 · 3 g/d fish oil · Men; age and health condition not reported | 3 g | 1 year | — |
| Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study 1997 · 6 g/d fish oil · Men; age and health condition not reported | 6 g | 1 year | — |
| Kinetics of the incorporation of dietary fatty acids into serum cholesteryl esters, erythrocyte membranes, and adipose tissue: an 18-month controlled study 1997 · 9 g/d fish oil · Men; age and health condition not reported | 9 g | 1 year | — |
| Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men 1997 · fish oil · Healthy men aged 29 to 60 years | 4 g | 4 weeks | — |
| Effects of dietary fish oil and soy phosphatidylcholine on neutrophil fatty acid composition, superoxide release, and adhesion 1998 · group 1, fish oil supplement · healthy volunteers matched for sex and age | 20 mL | 2 weeks | — |
| The impact of fish oil and/or probiotics on serum fatty acids and the interaction with low-grade inflammation in pregnant women with overweight and obesity: secondary analysis of a randomised controlled trial 2024 · fish oil + probiotics · Pregnant women with overweight or obesity, recruited in early pregnancy before 18 gestational weeks | 4.8 g | 150 days | 91 |
| A pilot randomised controlled trial to reduce colorectal cancer risk markers associated with B-vitamin deficiency, insulin resistance and colonic inflammation 2005 · treatment arm · Adults aged 44–80 with previously resected colonic adenomatous polyps or intramucosal carcinoma | 6 g | 4 weeks | 50 |
| Randomized controlled trial examining the effects of fish oil and multivitamin supplementation on the incorporation of n-3 and n-6 fatty acids into red blood cells 2014 · Fish Oil, 3 g + Multivitamin · Healthy men and women aged 50–70 years | 3 g | 16 weeks | 43 |
| Predictors of change in omega-3 index with fish oil supplementation in peripheral artery disease 2017 · fish oil group · Adults with stable, mild or severe claudication due to peripheral arterial disease (Rutherford Class 1 to 3); primarily male, in their mid-sixties | 4.4 g | 30 days | 40 |
| Randomized controlled trial examining the effects of fish oil and multivitamin supplementation on the incorporation of n-3 and n-6 fatty acids into red blood cells 2014 · Fish Oil, 6 g + Multivitamin · Healthy men and women aged 50–70 years | 6 g | 16 weeks | 39 |
| A randomised comparison of increase in serum 25-hydroxyvitamin D concentration after 4 weeks of daily oral intake of 10 microg cholecalciferol from multivitamin tablets or fish oil capsules in healthy young adults 2007 · fish oil capsules · Healthy adults aged 19–49 years | 10 mcg | 4 weeks | 27 |
| Comparison of the effects of a phospholipid-enhanced fish oil versus krill oil product on plasma levels of eicosapentaenoic and docosahexaenoic acids after acute administration: A randomized, double-blind, crossover study 2023 · phospholipid-enhanced fish oil (PEFO) · Healthy adult men and women | 1 g | 1 day | 24 |
| Comparative Bioavailability of DHA and EPA from Microalgal and Fish Oil in Adults 2025 · fish oil arm · Adults aged 21–82, men and women, with fasting triglycerides of 149–450 mg/dL | 1.16 g | 14 weeks | 20 |
| Wax Ester Rich Oil From The Marine Crustacean, Calanus finmarchicus, is a Bioavailable Source of EPA and DHA for Human Consumption 2016 · Lovaza ethyl ester condition · Healthy adults; age and sex not specified | 465 mg | 1 day | 18 |
| Effects of oils rich in eicosapentaenoic and docosahexaenoic acids on immune cell composition and function in healthy humans 2004 · DHA · Healthy human subjects; age and sex not specified | 4.9 g | 4 weeks | — |
| DHA-rich Fish Oil Increases the Omega-3 Index and Lowers the Oxygen Cost of Physiologically Stressful Cycling in Trained Individuals 2017 · DHA-rich tuna fish oil (FO) · trained males; age and health condition not specified | 560 mg | 8 weeks | — |
| Gut microbial community and host intestinal gene expression with combined fish oil and soluble corn fiber compared with corn oil and maltodextrin: A randomized crossover trial in healthy older individuals 2025 · SCF + FO · Adults aged 50–75 years described as healthy older individuals | 7.7 g | 30 days | — |
| [Selenium concentration in erythrocytes of patients with rheumatoid arthritis. Clinical and laboratory chemistry infection markers during administration of selenium] 1997 · Selenium-supplemented group · Adults with rheumatoid arthritis | 30 mg/kg | 90 days | — |
| Long-term metabolic effects of n-3 polyunsaturated fatty acids in patients with coronary artery disease 1995 · fish-oil group · Patients with coronary artery disease; age range and sex not stated | 4 g | 39 weeks | 260 |
| Prevention of Potential Adverse Metabolic Effects of a Supplementation with Omega-3 Fatty Acids Using a Genetic Score Approach 2020 · n-3 PUFA supplementation · Adults; age, sex, and health condition not specified | 5 g | 6 weeks | 210 |
| Eicosapentaenoic and Docosahexaenoic Acids Attenuate Progression of Albuminuria in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease 2017 · Lovaza · Adults aged 36–80 with stable coronary artery disease and overweight/obesity or metabolic-syndrome features; included participants with and without type 2 diabetes | 3.36 g | 1 year | 147 |
| A low-fat spread with added plant sterols and fish omega-3 fatty acids lowers serum triglyceride and LDL-cholesterol concentrations in individuals with modest hypercholesterolaemia and hypertriglyceridaemia 2019 · Intervention group · Men and women aged 18–75 with fasting triglycerides of 1.40–5.60 mmol/L and LDL-C of 3.4–4.9 mmol/L | 1 g | 4 weeks | 130 |
| Supplementation With Carotenoids, Omega-3 Fatty Acids, and Vitamin E Has a Positive Effect on the Symptoms and Progression of Alzheimer's Disease 2022 · active group · People with mild-moderate Alzheimer's disease; age and sex not reported | 1 g | 1 year | 50 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 100 mg alpha-tocopheryl acetate daily phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 15 g | 5 weeks | 48 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 200 mg alpha-tocopheryl acetate daily phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 15 g | 5 weeks | 48 |
| Effects of interaction of RRR-alpha-tocopheryl acetate and fish oil on low-density-lipoprotein oxidation in postmenopausal women with and without hormone-replacement therapy 1996 · 400 mg alpha-tocopheryl acetate daily phase · Postmenopausal women, equally divided between those using and not using hormone-replacement therapy | 15 g | 5 weeks | 48 |
| Relationship between the omega-3 index and specialized pro-resolving lipid mediators in patients with peripheral arterial disease taking fish oil supplements 2017 · fish oil group · Adults aged 50 and older with symptomatic lower-extremity peripheral arterial disease and intermittent claudication | 4.4 g | 30 days | 40 |
| DHA-enriched fish oil reduces insulin resistance in overweight and obese adults 2020 · FO (fish oil) intervention · Men and women with abdominal obesity, without diabetes; mean age 50.9 ± 12.7 years | 2 g | 12 weeks | 38 |
| A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial 2019 · Omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation | 2 g | 12 weeks | 35 |
| Pesco-Vegetarian Food Components Promote Colonocyte Ferroptosis in Preclinical Mouse Models and a Randomized Crossover Trial in Healthy Human Adults 2026 · SCF+FO · 30 healthy adults | 7.7 g | 30 days | 30 |
| Gene expression and biological pathways in tissue of men with prostate cancer in a randomized clinical trial of lycopene and fish oil supplementation 2011 · fish oil · Men with newly diagnosed, favorable-risk prostate cancer on active surveillance | 3 g | 90 days | 27 |
| Efficacy of fish oil on serum of TNF α , IL-1 β , and IL-6 oxidative stress markers in multiple sclerosis treated with interferon beta-1b 2013 · fish oil group · Adults aged 18–55 with relapsing-remitting multiple sclerosis, treated with interferon beta-1b | 4 g | 1 year | 25 |
| Influence of fish oil supplementation on in vivo and in vitro oxidation resistance of low-density lipoprotein in type 2 diabetes 2003 · Fish oil group · Adults with type 2 diabetes | 4 g | 8 weeks | 23 |
| The impact of fish oil and wheat germ oil combination on mineral-bone and inflammatory markers in maintenance hemodialysis patients: a randomized, double-blind, placebo-controlled clinical trial 2017 · fish oil plus wheat germ oil group · Maintenance hemodialysis patients | 3 g | 120 days | 23 |
| Combination of arginine, glutamine, and omega-3 fatty acid supplements for perioperative enteral nutrition in surgical patients with gastric adenocarcinoma or gastrointestinal stromal tumor (GIST): A prospective, randomized, double-blind study 2018 · Study group (immunomodulating nutrient-enriched diet) · Adults aged 20 years or older with gastric adenocarcinoma or gastric GIST undergoing elective gastrectomy | 6.96 g | 19 days | 22 |
| Effect of chia seeds or concentrated fish oil on cardiometabolic risk markers in subjects with hypertriglyceridaemia: a parallel clinical trial 2024 · low-calorie diet with concentrated fish oil · Patients with hypertriglyceridaemia; age and sex not specified | 1.8 g | 8 weeks | 22 |
| Metabolic and endocrine effects of long-chain versus essential omega-3 polyunsaturated fatty acids in polycystic ovary syndrome 2011 · fish oil · Women aged 20–45 with PCOS and BMI 25–45 kg/m² | 2.15 g | 6 weeks | 21 |
| Modulation of blood oxylipin levels by long-chain omega-3 fatty acid supplementation in hyper- and normolipidemic men 2014 · LC n-3 PUFA supplementation · Men aged 24–48 years: 10 normolipidemic and 10 with mild combined hyperlipidemia | 5.04 g | 12 weeks | 20 |
| Effects of Long Chain Omega-3 Polyunsaturated Fatty Acids on Brain Function in Mildly Hypertensive Older Adults 2018 · LCn-3PUFA group · Adults aged 40–85 with borderline or mild hypertension and low fish/seafood intake | 1.6 g | 20 weeks | 19 |
| Effects of Maternal Fish Oil and/or 5-Methyl-Tetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-Up Study from the NUHEAL Randomized Controlled Trial 2020 · fish oil (FO) · Children born to healthy pregnant women who received fish oil during pregnancy; children were assessed at 9.5–10 years | 650 mg | — | 19 |
| Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial 2012 · oxidised fish oil · Healthy adults aged 18–50 years | 8 g | 7 weeks | 18 |
| DHA supplementation decreases serum C-reactive protein and other markers of inflammation in hypertriglyceridemic men 2009 · DHA oil group · Men aged 39–66 with hypertriglyceridemia | 7.5 g | 90 days | 17 |
| Oxidised fish oil does not influence established markers of oxidative stress in healthy human subjects: a randomised controlled trial 2012 · fish oil · Healthy adults aged 18–50 years | 8 g | 7 weeks | 17 |
| Fish oil supplementation induces expression of genes related to cell cycle, endoplasmic reticulum stress and apoptosis in peripheral blood mononuclear cells: a transcriptomic approach 2014 · FO group · Healthy men and women aged 18–50 years | 8 g | 7 weeks | 17 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · FO (fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 2 g | 12 weeks | 17 |
| Curcumin and/or omega-3 polyunsaturated fatty acids supplementation reduces insulin resistance and blood lipids in individuals with high risk of type 2 diabetes: a randomised controlled trial 2019 · CC-FO (curcumin plus fish oil) · Adults aged 30–70 at high risk of type 2 diabetes or with impaired fasting glucose or impaired glucose tolerance; men and women | 2 g | 12 weeks | 16 |
| Effects of Maternal Fish Oil and/or 5-Methyl-Tetrahydrofolate Supplementation during Pregnancy on Offspring Brain Resting-State at 10 Years Old: A Follow-Up Study from the NUHEAL Randomized Controlled Trial 2020 · FO + 5-MTHF · Children born to healthy pregnant women who received fish oil and 5-methyl-tetrahydrofolate during pregnancy; children were assessed at 9.5–10 years | 650 mg | — | 14 |
| A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease 2014 · ω-3 + LA · Adults aged 55 years or older with probable Alzheimer’s disease | 3 g | 1 year | 13 |
| Eicosapentaenoic acid decreases inflammation and improves glucose homeostasis in patients with burns: a randomized clinical trial 2025 · EPA-rich fish oil · Adults aged 18–65 with non-severe burns covering less than 20% of total body surface area | 1.5 g | 3 weeks | 12 |
| Effect of 21-Day Omega-3 Polyunsaturated Fatty Acid Supplementation on Exercise-Induced Secretory Factors and Inflammation Status in Young Men: A Randomized Double-Blind Trial 2026 · supplementation group · Physically active, healthy men aged approximately 22 years | 5 g | 3 weeks | 12 |
| Whole blood production of thromboxane, prostacyclin and leukotriene B4 after dietary fish oil supplementation in man: effect of vitamin E 1996 · FO · adult men; no condition stated | 30 mL | 4 weeks | 12 |
| Whole blood production of thromboxane, prostacyclin and leukotriene B4 after dietary fish oil supplementation in man: effect of vitamin E 1996 · FO+E · adult men; no condition stated | 30 mL | 4 weeks | 12 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 4.4 g | 90 days | 11 |
| Fish Oil Increases Specialized Pro-resolving Lipid Mediators in PAD (The OMEGA-PAD II Trial) 2019 · fish oil group · Men aged 50 years or older with peripheral artery disease and intermittent claudication | 4.4 g | 90 days | 11 |
| Effect of exercise on FA profiles in n-3 FA-supplemented and -nonsupplemented premenopausal women 2002 · fish oil group · Sedentary premenopausal women | 5.9 g | — | 10 |
| Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial 2012 · FO-N (normolipidemic fish oil group) · Men aged 29–51 years with normolipidemia | 2.7 g | 12 weeks | 10 |
| n-3 Polyunsaturated Fatty Acid Supplementation Has No Effect on Postprandial Triglyceride-Rich Lipoprotein Kinetics in Men with Type 2 Diabetes 2016 · n-3 PUFA (fish oil) supplementation · Men with type 2 diabetes; mean age 54.7 ± 7.6 years | 5 g | 8 weeks | 10 |
| Effect of dietary n-3 PUFA supplementation on the muscle transcriptome in older adults 2016 · n-3 PUFA group · Healthy men and women aged 60–85 years | 4 g | 26 weeks | 10 |
| Fish oil supplementation versus gemfibrozil treatment in hyperlipidemic NIDDM. A randomized crossover study 1996 · Fish oil (FO) · Patients with hyperlipidemic non-insulin-dependent diabetes mellitus; age and sex not reported | 22 mL | 2 weeks | 10 |
| Different gene expression profiles in normo- and dyslipidemic men after fish oil supplementation: results from a randomized controlled trial 2012 · FO-D (dyslipidemic fish oil group) · Men aged 29–51 years with dyslipidemia | 2.7 g | 12 weeks | 9 |
| Fish oil supplementation suppresses resistance exercise and feeding-induced increases in anabolic signaling without affecting myofibrillar protein synthesis in young men 2016 · Fish oil (FO) group · Resistance-trained men aged 21–24 years | 5 g | 8 weeks | 9 |
| Effects of a small quantity of omega-3 fatty acids on cardiovascular risk factors in NIDDM. A randomized, prospective, double-blind, controlled study 1994 · fish oil group · Adults with non-insulin-dependent diabetes mellitus (NIDDM) | 5 g | 6 weeks | 9 |
| Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects 1994 · fish oil · Subjects without cystic fibrosis; mean age 13.4 years | 8 g | 6 weeks | 8 |
| Oral absorption of omega-3 fatty acids in patients with cystic fibrosis who have pancreatic insufficiency and in healthy control subjects 1994 · fish oil · Patients with cystic fibrosis and pancreatic insufficiency; mean age 12.2 years | 8 g | 6 weeks | 7 |
| Omega 3 Improves Both apoB100-containing Lipoprotein Turnover and their Sphingolipid Profile in Hypertriglyceridemia 2020 · n-3 supplementation · Six subjects with hypertriglyceridemia; age and sex not reported | 3 g | 60 days | 6 |
| Consumption of fish oil leads to prompt incorporation of eicosapentaenoic acid into colonic mucosa of patients prior to surgery for colorectal cancer, but has no detectable effect on epithelial cytokinetics 1999 · FO group · Adults with colonic carcinoma awaiting surgery; ages and sex distribution as reported in the abstract | 4 g | 12 days | — |
| Differential effects of dietary supplementation with fish oil or soy lecithin on human platelet adhesion 1999 · fish oil supplement group · Human volunteers; age, sex, and health status not specified | 20 mL | 15 days | — |
| Encapsulated fish oil enriched in alpha-tocopherol alters plasma phospholipid and mononuclear cell fatty acid compositions but not mononuclear cell functions 2000 · fish oil (FO) · Healthy subjects; age and sex not specified | 9 g | 12 weeks | — |
| Moderate fish-oil supplementation reverses low-platelet, long-chain n-3 polyunsaturated fatty acid status and reduces plasma triacylglycerol concentrations in British Indo-Asians 2004 · Fish-oil group · British Indo-Asian Sikhs and Europeans; adults, age and weight matched between ethnic groups | 4 g | 12 weeks | — |
| Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study 2004 · n-3 PUFA group · Healthy adult males | 12 g | 8 weeks | — |
| Reduced effect on apoptosis of 4-hydroxyhexenal and oxidized LDL enriched with n-3 fatty acids from postmenopausal women 2005 · low dose LFO · healthy postmenopausal women | 7 g | 5 weeks | — |
| Fish-oil esters of plant sterols improve the lipid profile of dyslipidemic subjects more than do fish-oil or sunflower oil esters of plant sterols 2006 · FO-PS · Moderately overweight, hyperlipidemic adults; age and sex not specified | 5.4 g | 4 weeks | — |
| Independent and interactive effects of plant sterols and fish oil n-3 long-chain polyunsaturated fatty acids on the plasma lipid profile of mildly hyperlipidaemic Indian adults 2009 · Plant sterol-enriched yoghurt drink and fish oil capsules · Adults aged 35–55 years with mild hypercholesterolaemia | 2 g | 4 weeks | — |
| Nitric oxide enhancement and blood pressure decrease in patients with metabolic syndrome using soy protein or fish oil 2010 · fourth group · Women with metabolic syndrome | 3 g | 90 days | — |
| ALOX5 gene variants affect eicosanoid production and response to fish oil supplementation 2011 · fish oil · African American adults aged 20–59 years, 68% female; no specific condition stated | 5 g | — | — |
| [Effect on the lipid profile of diet supplemented with fish oil concentrate] 1990 · n-3 treated group · male and female patients with cholesterol values higher than 7.0 mmol/l | 6 g | 12 weeks | — |
| Effects of extra virgin olive oil and fish oil on lipid profile and oxidative stress in patients with metabolic syndrome 2015 · fish oil and extra virgin olive oil group (FOO) · Adults with metabolic syndrome; mean age 51.45 years; 81 women and 21 men across the study | 3 g | 90 days | — |
| Treatment for 6 months with fish oil-derived n-3 polyunsaturated fatty acids has neutral effects on glycemic control but improves dyslipidemia in type 2 diabetic patients with abdominal obesity: a randomized, double-blind, placebo-controlled trial 2017 · fish oil group · Adults with type 2 diabetes and abdominal obesity; mean age 65.4 years; 35 men and 64 women completed the study | 4 g | 26 weeks | — |
| Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects 2020 · Saury oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease | 12 g | 8 weeks | — |
| Supplementation with saury oil, a fish oil high in omega-11 monounsaturated fatty acids, improves plasma lipids in healthy subjects 2020 · Control oil · Healthy adults, mean age 34.8 years; 60% female; no history of chronic disease | 12 g | 8 weeks | — |
| Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults 2020 · EPA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease | 12 g | 8 weeks | — |
| Comparison of Omega-3 Eicosapentaenoic Acid Versus Docosahexaenoic Acid-Rich Fish Oil Supplementation on Plasma Lipids and Lipoproteins in Normolipidemic Adults 2020 · DHA-rich fish oil · Healthy adults aged 23–44, without chronic or serious disease | 12 g | 8 weeks | — |
| Postprandial lipaemia following consumption of a meal enriched with medium chain saturated and/or long chain omega-3 polyunsaturated fatty acids. A randomised cross-over study 2021 · coconut oil + fish oil (COFO) · healthy adults | 6 g | 1 day | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + placebo · Overweight or obese pregnant women at increased risk for gestational diabetes | 2.4 g | — | — |
| The Impacts of Fish Oil and/or Probiotic Intervention on Low-Grade Inflammation, IGFBP-1 and MMP-8 in Pregnancy: A Randomized, Placebo-Controlled, Double-Blind Clinical Trial 2020 · fish oil + probiotics · Overweight or obese pregnant women at increased risk for gestational diabetes | 2.4 g | — | — |
| Modification of subcutaneous white adipose tissue inflammation by omega-3 fatty acids is limited in human obesity-a double blind, randomised clinical trial 2022 · Fish oil · Adults aged 18–65 years, healthy normal-weight participants and participants living with obesity without diagnosed metabolic complications | 3 g | 12 weeks | — |
| Comparative effectiveness of adding omega-3 and Manuka honey combination to conventional therapy in preventing and treating oxidative stress in pediatric β-thalassemia major - a randomized clinical trial 2023 · Omega-3 fish oil plus Manuka honey · Pediatric patients with β-thalassemia major | 1 g | 304 days | — |
| Effects of hydrolyzed collagen alone or in combination with fish oil on the gut microbiome in patients with major burns 2024 · Collagen and fish oil group · Adults aged 18–60 years with 20–45% total body surface area burns | 10 mL | 2 weeks | — |
| Effects of dietary supplementation of fish oil plus vitamin D(3) on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial 2024 · FO + D group · Subjects studied in relation to nonalcoholic fatty liver disease risk factors; age and sex not reported | 2.34 g | 90 days | — |
| Fish diet, fish oil and docosahexaenoic acid rich oil lower fasting and postprandial plasma lipid levels 1996 · fish oil group · Healthy male university students | 4 g | 15 weeks | — |
| Effect of garlic and fish-oil supplementation on serum lipid and lipoprotein concentrations in hypercholesterolemic men 1997 · 900 mg garlic/d + 12 g fish oil/d · Men with moderate hypercholesterolemia | 12 g | 12 weeks | — |
| A new nutraceutical (Livogen Plus®) improves liver steatosis in adults with non-alcoholic fatty liver disease 2022 · Nutraceutical (Livogen Plus®) · Adults aged 30–75 with hepatic steatosis (NAFLD), without diabetes | 667 mg | 12 weeks | 70 |
| A combination of omega-3 and plant sterols regulate glucose and lipid metabolism in individuals with impaired glucose regulation: a randomized and controlled clinical trial 2019 · PS plus omega-3 fatty acids group · Adults aged 51–65 with impaired glucose regulation | 2 g | 12 weeks | 41 |
| Fish oil and antioxidants alter the composition and function of circulating mononuclear cells in Crohn disease 2004 · fish-oil group · Patients with Crohn disease and raised C-reactive protein concentrations or erythrocyte sedimentation rates; age and sex not stated | 2.7 g | 24 weeks | 31 |
| High-dose fish oil and antioxidants in Crohn's disease and the response of bone turnover: a randomised controlled trial 2005 · fish oil plus antioxidants · Patients with Crohn's disease and currently or recently raised biochemical markers of inflammation | 2.7 g | 24 weeks | 31 |
| A Mixed Flavonoid-Fish Oil Supplement Induces Immune-Enhancing and Anti-Inflammatory Transcriptomic Changes in Adult Obese and Overweight Women-A Randomized Controlled Trial 2016 · Q-Mix · Women aged 40–70 years who were overweight or obese (BMI ≥25 kg/m²), without the listed major diseases | 200 mg | 10 weeks | 24 |
| The immunomodulatory effects of fish-oil supplementation in elite paddlers: A pilot randomized double blind placebo-controlled trial 2015 · fish-oil capsules · male elite paddlers undertaking an increasing exercise program | 6 g | 4 weeks | 11 |
| Omega-3 supplementation combined with anti-vascular endothelial growth factor lowers vitreal levels of vascular endothelial growth factor in wet age-related macular degeneration 2014 · Group 1 (Vitalux plus Omega-3) · Adults with active wet age-related macular degeneration who had previously received anti-VEGF treatment | 1.05 g | — | 10 |
| Comparison of seal oil to tuna oil on plasma lipid levels and blood pressure in hypertriglyceridaemic subjects 2009 · fish oil capsules · Hypertriglyceridaemic volunteers recruited from the Wollongong community; age and sex not reported | 1 g | 6 weeks | — |
| Potential Modulation of Inflammation by Probiotic and Omega-3 Supplementation in Elderly with Chronic Low-Grade Inflammation-A Randomized, Placebo-Controlled Trial 2022 · Active treatment group · Adults aged 65–80 with low-grade inflammation (hs-CRP 1.5–6 mg/L) and BMI 18.5–27 kg/m² | 1.1 g | 8 weeks | — |
| Synbiotic Bacillus megaterium DSM 32963 and n-3 PUFA Salt Composition Elevates Pro-Resolving Lipid Mediator Levels in Healthy Subjects: A Randomized Controlled Study 2024 · Fish oil group · Healthy men and women aged 30–75 years, selected as at-risk individuals with omega-3 index ≤6.5% and elevated AGEs and/or hsCRP | 180 mg | 4 weeks | — |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation alone · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 3 years | 401 |
| Red Blood Cell Omega-3 Fatty Acid Composition and Psychotropic Drug Use in Older Adults: Results from the MAPT Study 2019 · PUFA supplementation + multidomain intervention · Adults aged 70 years or older with a memory complaint, an instrumental activity limitation, or slow walking speed | 800 mg | 3 years | 399 |
| Supplementation of krill oil with high phospholipid content increases sum of EPA and DHA in erythrocytes compared with low phospholipid krill oil 2015 · Fish oil · Healthy men and non-pregnant women aged 18–49 years | 600 mg | 4 weeks | 24 |
| Protective effect of fish oil supplementation on DNA damage induced by cigarette smoking 2013 · fish oil group · adult male never-smokers | 1 g | 90 days | 20 |
| Statin dose reduction with complementary diet therapy: A pilot study of personalized medicine 2018 · Responders receiving nutraceuticals with standard statin therapy · Adults with dyslipidemia and type 2 diabetes treated with statins and hypoglycemic medication, classified as nutraceutical responders; 3 men and 7 women, mean age 62.1 years | 1.7 g | 6 weeks | 10 |
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer 2007 · 15-g dose group · Patients with advanced lung cancer; age and sex not reported | 45 g | — | — |
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer 2007 · 12-g dose group · Patients with advanced lung cancer; age and sex not reported | 36 g | — | — |
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer 2007 · 9-g dose group · Patients with advanced lung cancer; age and sex not reported | 27 g | — | — |
| Effects of eicosapentaenoic and docosahexaenoic n-3 fatty acids from fish oil and preferential Cox-2 inhibition on systemic syndromes in patients with advanced lung cancer 2007 · 6-g dose group · Patients with advanced lung cancer; age and sex not reported | 18 g | — | — |
| Effects of extra virgin olive oil and fish oil on lipid profile and oxidative stress in patients with metabolic syndrome 2015 · fish oil group (FO) · Adults with metabolic syndrome; mean age 51.45 years; 81 women and 21 men across the study | 3 g | 90 days | — |
| Supplementation of Catfish (Clarias gariepinus) Oil Enriched with Omega-3 Soft Capsule Improves Oxidative Stress and Cognitive Function in Elderly 2020 · CFO (commercial fish oil) · Elderly people aged over 60 years with dyslipidemia | 1 g | 90 days | — |
| Effects of dietary supplementation of fish oil plus vitamin D(3) on gut microbiota and fecal metabolites, and their correlation with nonalcoholic fatty liver disease risk factors: a randomized controlled trial 2024 · FO group · Subjects studied in relation to nonalcoholic fatty liver disease risk factors; age and sex not reported | 2.34 g | 90 days | — |